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Several plants have been used extensively for the treatment of diabetes and its 
related conditions throughout the world. Most plants contain a diverse range of 
phytochemicals and can often have anti-diabetic effects. Among the multitude of plants, 
Momordica charantia L. is a well-known plant, and it is cultivated as a medicinal 
vegetable for the management of diabetes in tropical and subtropical areas such as East 
Africa, Asia, South America, and the Caribbean. Various extracts and isolated compounds 
have been reported to have significant anticancer and antitumor activity, glucose reducing 
the effect and AMP-activated protein kinase activities. To further understand the role of 
compounds from this plant, the current thesis work describes the isolation, structure 
elucidation, and bioactivities of compounds from the bitter melon. 
   In the first study, three cucurbitane-type triterpene aglycones such as four 
compounds were isolated from the EtOAc extract of bitter melon fruit. Charantoside XI is 
a novel cucurbitane-type triterpene containing a carboxylic acid from Momordica 
charantia. The isolated compounds were assessed for their anti-diabetic and anti-
inflammatory activities.  
In the second study, six triterpene glycosides such as momordicoside I, F1, K, F2, 
G, and Karaviloside XI, a new phenolic derivative 2-hydroxy-5-O-β-D-xylopyranosyl 
benzoic acid, benzoic acid, phenylalanine, and quercetin-7-O-β-glucopyranoside were 
isolated from the polar extracts of bitter melon and evaluated for in vitro and in silico anti 
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CHAPTER 1  
INTRODUCTION 
 
The numerous plants have been explored from ancient times by man for the 
treatment of diseases. In the last few decades, there is a multitude of research carried out 
on plants mentioned in ancient literature for the treatment of diabetes, and related 
conditions. 1 Many of the presently available drugs for the treatment of various metabolic 
diseases have been derived directly or indirectly from the plants. 2 Most plants contain a 
diverse range of phytochemicals and can often have anti-diabetic effects. Among the 
multitude of plants, Momordica charantia is a well-known plant belongs to family 
Cucurbitaceae, and it is cultivated as a medicinal vegetable for the management of 
diabetes in tropical and subtropical areas of the world including East Africa, Asia, South 
America, and the Caribbean. 3  The origin of  this plant is in Asia, and the precise place is 
unclear in-between China and India. 4  
Diabetes mellitus is the most common chronic disease and considered as major 
leading causes of death in the world. According to the American Diabetes Association, 
around 30.3 million Americans found to have diabetes in 2015. 5 It is estimated that this 
figure will reach 330 million by 2030. The progression of Type II diabetes is typically 
characterized by insulin resistance, loss of normal β-cell activity and followed by the 
progressive decline of pancreatic β-cell function that results in insufficient insulin 
secretion.6 Momordica charantia L. is commonly used traditional medicinal plant by the 




Type II diabetes. Data from in vitro, in vivo and preclinical studies, suggest that bitter 
melon extracts have a moderate hypoglycemic effect. Also, numerous pharmacological 
studies also proved its antidiabetic and hypoglycaemic effects through various postulated 
mechanisms.7   
Among various health benefits, the anti-diabetic activity of bitter melon has been 
related to various triterpenoids. To date, more than 240 bitter melon cucurbitane 
triterpenoids have been reported from different plant parts including leaves, stems, roots, 
fruits, and vines. 8 Isolated cucurbitane triterpenoids and their glycosides have been 
reported to have significant anticancer, 9 and antitumor activity, 10 glucose reducing effect 
11, and AMP-activated protein kinase activities. 12 Among these momordicosides, K and 
L, and momordicines I and II were believed to be responsible for the bitter taste of the 
fruit. Charantin is one of the major glycoside isolated from the fruits of M. charantia that 
may have insulin-like properties.13 Aglycones of charantin were isolated and identified as 
sitosterol and stigmastadienol.  However, the concentration or bioefficacy of charantin on 
diabetes have not been well characterized. 14 In response to accumulating data correlating 
bitter melon and successful diabetes management, several preclinical and clinical trials 
have been conducted. Over 20 clinical studies have hypothesized that extracts and 
bioactive compounds present in the bitter melon may be responsible for the hypoglycemic 
activity.  15 16 
In conclusion, in case of in vivo and in vitro, several pre-clinical and clinical 
studies validate the hypoglycaemic potential of bitter melon extracts from the fruit, seeds, 




anti-diabetic mechanism of action of M. charantia extracts on type 2 diabetes due to 
intermittent results. Due to lack of proper controls, and poor methodologies, these 
preliminary studies are not interpretable. So, reliable in vitro and in vivo studies are 
required to prove the potential anti-diabetic activity of M. charantia. Hence, the present 
study focused on in vitro screening for α-amylase and α-glucosidase. 
Overall, accumulative evidence demonstrated that health-promoting properties of 
bitter gourd are due the specific natural compounds. 20,21 Existing literature suggests 
that M. charantia consists of an array of natural compounds, which makes it a functional 
food, especially in the reducing risk from diabetes. However, the exact mechanism of each 
of these compounds in the observed antidiabetic potential of M. charantia is still obscure.  
Published reports include mostly isolation of compounds using plants or fruit material and 
extracting with toxic solvents with unreproducible methods. Therefore, it is imperative 
that pre-clinical and clinical evaluation studies should employ standardized preparation of 
M. charantia and provide comprehensive details of extraction procedure used to isolate 
either the active ingredient or list the details of the extraction solvent used (e.g., water, 
ethanol, methanol, etc.). Therefore, our study focussed on precise methods to isolate 
bioactive compounds from M. charantia using different methods of extraction, the solvent 
used for extraction and reproducible chromatography techniques. 
Therefore, in the present study, we isolated and characterized active components 
from M. charantia, and confirmed their in vitro antidiabetic activity. Furthermore, the In 




compounds. Taken together, the present study will contribute to establishing M. 
charantia as a “functional food for diabetes.”  
The hypothesis for this thesis is that the bitter compounds purified from M. 
charantia are associated with potential antidiabetic and anti-inflammatory activities 
The hypothesis has been divided into three objectives:  
1. To isolate and structure elucidation of natural compounds from M. charantia. 
2. To assess in vitro antidiabetic and anti-inflammatory potential of purified 
compounds. 
3. To conduct in silico molecular docking studies of purified compounds to confirm 













CHAPTER 2  
REVIEW OF LITERATURE 
 
2.1 Characteristics of Momordica charantia 
 
M. charantia is a vegetable with high nutrition value, and it has a remarkably long 
history of use, both as a food and medicine. M. charantia perennial slender, climber annual 
vine, grows 2-3 m long. The fruit is 2-10 cm long (up to 20 cm in cultivated varieties), 
and covered with longitudinal ridges and warts. The plant and fruit have a characteristic 
bitter taste. Hence it is commonly known as bitter melon or bitter gourd.22 Bitter melon 
also gained many familiar names, indicating its diversified usage in numerous cultures. 
The plant thrives in tropical areas of Asia, Amazon, East Africa, and the Caribbean.  
 
2.2 Nutritional value of M. charantia 
 
Bitter gourd (Momordica charantia L.) is one of the important cucurbitaceous 
vegetables, and it is considered as a prized vegetable among the other cucurbits because 
of its high nutritious value especially ascorbic acid and iron. 23 The fruit has a high calorific 
value of 241.66 Kcal/100 g compared to leaves 213.26 Kcal/100 g and seeds 176.61 
Kcal/100 g. Leaves of Momordica charantia is the rich source of calcium (20510 ppm) 
compared with potassium (413 ppm), sodium (2200 ppm) as well as zinc (120 ppm). 




(0.03 ppm), vitamin E (α-tocopherol) (800 ppm), folic acid (20600 ppm), cyanocobalamin 
(5355 ppm) and ascorbic acid (66000 ppm). 24, 25 
 
2.3 Medicinal uses of M. charantia 
 
Traditionally M. charantia has been used as a medicine in many developing 
countries. Indigenous populations of Asia and Africa have been using different extracts of 
M.charantia as a tonic, stomachic, stimulant, emetic, antibilious, laxative, and alternative. 
26 The traditional Indian medicines indicate the usage of M. charantia typically for 
treatment of wounds, treatment of worms and parasites (internally and externally). In 
Turkish folk medicine, bitter gourd is used for the treatment of gastric ailments including 
peptic ulcers.27 The various plant's parts have been used traditionally for the treatment of 
hyperlipidemia, digestive disorders, microbial infections, and menstrual problems. 28  
Also, the plant is well-known for its medicinal properties, including antidiabetic, 
anticancer, anti-inflammation, antivirus, and cholesterol-lowering effects. Several 
phenolic constituents in M. charantia may have the potential as an antioxidant, 
antimutagen, antitumor, anti-inflammatory, and anticarcinogenic properties. 25, 29 M. 
charantia extract can also be used as a potential antibacterial agent to treat infections 
caused by Escherichia coli, Salmonella, Staphylococcus aureus, Staphylococcus, 
Pseudomonas, and Streptobacillus. 30 Protein isolated from M. charantia has been shown 
to possess broad antiviral activity against different subtypes of influenza A (A/New 




31 Regarding its anti-inflammatory activity, M. charantia decreases prostaglandin E2 
(PGE2), interleukin (IL)-7 and tumor necrosis factor-α and increases transforming growth 
factor- and IL-10 secretion in RAW 264.7 macrophages, Caco-2 cells, and THP1 cells. 32, 
33, 34 Several studies also showed the M. charantia fruit extract exhibits 
hypocholesterolemia, hypotriglyceridemic effects in the STZ-induced diabetic rat. 35 
Many in vitro and in vivo preliminary studies of M. charantia crude extract have shown 
anti-cancer activity against choriocarcinoma, lymphoid leukemia, lymphoma, melanoma, 
breast cancer, skin, tumor, and prostatic cancer. 36, 37 
 
2.4 Phytochemical profile of M. charantia 
 
M.charantia contains an array of novel and biologically active phytochemicals. 
Based on the varieties, origin and harvesting times including maturity stages (immature, 
mature and ripe fruits) the chemical composition varies in bitter melon. Despite its 
characteristic bitter taste, bitter melon is consumed in many cultures due to its reported 
potential health benefits attributed to the presence of health-promoting compounds, such 
as polyphenols, cucurbitane type triterpenoids, and their glycosides, saponins, 
carotenoids, flavonoids, sterols,  alkaloids, reducing sugars, resins, oils, and free acids. 7, 
38 Some of the important simple phenols, benzoic acid derivatives compounds such as 
gallic acid, protocatechuic acid, gentisic acid, vanillic acid, chlorogenic acid, tannic acid, 
caffeic acid, p-coumaric acid, p-hydroxybenzoic acid, chlorogenic, syringic acid, ferulic 




fruit is emerald green color during the young stage and turns to orange-yellow when ripe. 
As the fruit ripens, the fruit becomes less bitter, and it contains a high content of 
carotenoids. The fruit is divided into three irregular valves during full maturity and fruit 
curl backward and releases numerous reddish-brown or white seeds encased in scarlet 
arils. 41 Bitter melon has recently received much attention due to cucurbitane-type 
triterpenoids and their various biological activities. The natural cucurbitacins constitute a 
group of various triterpenoid substances which are known for their bitterness and toxicity. 
Cucurbitacins were initially isolated from the Cucurbitaceae, and were later identified, 
either non-glycosylated or glycosylated, in plants of the families Brassicaceae, 
Scrophulariaceae, Begoniaceae, Elaeocarpaceae, Datiscaceae, Desfontainiaceae, 
Polemoniaceae, Primulaceae, Rubiaceae, Sterculiaceae, Rosaceae, and Thymelaeaceae.42 
The basic skelton of cucurbitane tritepenoid is shown in Figure 1 and Table 1 summarizes 
various natural compounds isolated from M. charantia and their biological activities. 
Some proteins in bitter melon including MAP-30, MRK29, ribosome inactivating protein 
gelonin, α-momocharin, β-momocharin, and momordicin and they can treat tumors and 
HIV. 43, 44  In the last four decades, using various parts of the plant and extraction 
techniques, more than 240 cucurbitane-type triterpenoids and their glycosides have been 


























Table 1 Reported natural compounds and their biological activities isolated from M. charantia. 
 




 reduction in the hepatic 






















* (23E)-cucurbita-5,23,25-triene-3 β,7 















* 3 β ,25-dihydroxy-7 β -methoxy-
cucurbita- 
5,23(E)-diene 
* 3β -hydroxy-7β ,25-
dimethoxycucurbita- 
5,23(E)-diene 
* 3-O- β -D-allopyranose, 7 β ,25-
dihydroxycucurbita- 
5,23(E)-dien-19-al. 
in vivo hypoglycemic 
activity 
 48 
5 Dried fruit Cucurbitane-Type Triterpenes 
* karavilagenins A, B, and C 
cucurbitane-type 
triterpene glycosides 

















Table 1 continued 





* momordicoside M, N, and O 
  51 
8 Stems Cucurbitane-Type Triterpenoids 
* cucurbita-5,23(E)-diene-3β,7 β,25-
triol  






  52 
9 Roots Cucurbitane Glycosides 
* kuguaglycosides A– H 
* karaviloside III, 
*karavilosideV  
*karaviloside XI, and  
*momordicoside K 
 53 
10 Roots Trinorcucurbitane triterpenoids 
* kuguacins A–E 
  54 















*momordicosides Q, R, 
S, and T 
Activation of the AMPK 
Pathway 
 56 
13 vines and 
leaves 
cucurbitane triterpenoids 





Cucurbitane triterpene glycosides 






Table 1 continued  
S. No Parts Natural compounds Bioactivity Reference 









cytoprotective activity  59 






  60 
17 Stems multiflorane triterpenoid  
* 3β-hydroxymultiflora-8- 
en-17-oic acid 
* cucurbita-1(10),5,22, 24-tetraen-3α-ol 
* 5 β,19 β -epoxycucurbita-6,22,24-
trien- 
3a-ol 
Antioxidant activity 61 
18 Stems Octanorcucurbitane Triterpenoids 









* momordicine I  
* momordicine II 
* 3-hydroxycucurbita-5,24-dien-19-al-
7,23-di-O-β- 
glucopyranoside (4), and 
kuguaglycoside 
 
In-vitro insulin secretion 
activity 
 62 
20 Fruit cucurbitane triterpenoids 
* (23E)-5β,19-epoxycucurbita-6,23,25-
triene-3b-ol 
* (19R, 23E)-5 β,19-epoxy- 
19-ethoxycucurbita-6,23-diene-3b,25-
diol 


















Table 1 continued 
S. No Parts Natural compounds Bioactivity Reference 
22 Stems Sterols 
* 5α,6α -epoxy-3 β -hydroxy-
(22E,24R)-ergosta-8,22-dien-7-one 
* 5α,6 α -epoxy-(22E,24R)-ergosta-
8,22-diene-3β,7 α-diol 
 
  65 




24 Fresh fruit cucurbitane-type triterpeneglycosides 







Cytotoxicity Activities 67 






* (23R*)-23-O-methylmomordicine IV 












antitumor activity 21 























Table 1 continued 
 
 
2.5 Anti-diabetic effect of M. charantia 
 
Numerous traditional herbal remedies have been used to treat diabetes in Asia and 
other developing countries.72, 73  Among them M. charantia is one of the plants that has 
been investigated thoroughly for the treatment of diabetes and related conditions. The 
wide range of biological activities has been proven by the support of many scientific 
investigations for the beneficial effects of M. charantia. Among many scientific 
investigations, plant stands out for its promising antidiabetic activity. 7 Previous in vitro 
and in vivo pharmacological investigations on M. charantia have demonstrated that the 
S. No Parts Natural compounds Bioactivity Reference 
28 fruits cucurbitane-type triterpene glycosides 
 
*charantosides D-G  




* kuguacin X 
* kuguaglycoside I 
 






methoxycucurbita-6,24-dien- 3 β,23-diol 
* (19S)-5 β,19-epoxy-19-
methoxycucurbita-6,24-dien-3 β,23-diol 












extracts and bioactive compounds help in regulating glucose uptake, 74, 75  stimulate insulin 
secretion from pancreatic cells, 62, 76 protect pancreatic 𝛽-cells from inflammatory 
conditions, 77 display insulin mimetic activities and reduce lipid accumulation in adipose 
cells. 78 Other evidence indicates that bitter melon extracts may decrease hepatic 
gluconeogenesis, increase hepatic glycogen synthesis, and increase peripheral glucose 
oxidation in erythrocytes and adipocytes. 3 Some of the purified cucurbitane type 
triterpene glycosides have showed AMP-activated protein kinase activity which is a 
plausible hypoglycemic mechanism of M. charantia.6, 79 The anti-diabetic activity, due to 
saponins present in M. charantia, is attributed in reversing atrophy of pancreatic islets of 
β cells, which in turn helps in insulin secretion and an increase in hepatic glycogen level. 
In addition, many in vitro studies have been conducted on investigating effects of crude 
extracts, isolated compounds on inhibition of α-glucosidase and α-amylase and PTP 1B 
inhibition. 80,81 Several in vivo studies demonstrate that M. charantia extract causes 
hypoglycemia, (stimulation of peripheral skeletal muscle glucose utilization), inhibits 
intestinal glucose uptake, inhibits adipocyte differentiation, suppresses key gluconeogenic 
enzymes (glucose-6-phosphatase and fructose-1,6-bisphosphatase), preserves pancreatic 
β cells and insulin secretory function, and reduces serum lipid levels. 
 
2.6 Clinical trials  
 
Few clinical trials on M. charantia have been observed to reduce serum glucose 




clinical trials have been conducted using plant parts or formulated products. Table 2 lists 
some of the previously conducted clinical trials across the world.  In many clinical studies 
the results seem promising. However, some previous experiments had serious 
methodologic errors including small sample size, and poorer statistical analyses and most 
did not even have a control group and some studies are randomized trials. For these 
reasons, firm conclusions on effectiveness could not be drawn. Also in all these studies, 
the toxicity, dosage, and adverse effects have not been systematically assessed.3, 17 
 
Table 2 Reported clinical trials on M. charantia. 
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(p = 0.021). 
Yes 86 
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Table 2 continued 
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Table 2 continued 
 
 
2.7 Simple and quick tools for dereplication of antidiabetic principles using In-silico 
molecular docking  
 
Substantial data are available in the category of secondary metabolites of M. 
charantia like isolation, identification, and characterization. Moreover, in the past two 
decades, many additional bioactive secondary metabolites were isolated from bitter gourd 
due to considerable progress in techniques for dereplication, isolation, and analysis. 
Interestingly, newly isolated compounds were only in minute concentration.  Therefore, 
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commercially available natural compounds are too expensive which represents a 
bottleneck for in-depth biological characterization. To overcome these issues and 
moreover as a way to close the knowledge gap of this vast pool of pharmacologically 
almost untapped pure constituents, the application of in silico-based methods might be a 
promising strategy for prioritizing bio-assays. Again, in this study, in silico experiments 
helps to explore the possible mechanism of action of these metabolites through the 
inhibition of α-amylase and α-glucosidase. The results obtained from this in 
silico approach will be compared to experimental bioactivity data to distinguish between 
true and false positives or negatives. 
Some of the programs used for virtual screening and docking studies are 
AutoDock, CLC drug discovery workbench, DOCK, FlexX, FRED, Glide, GOLD, and 
MOE. These programs help to understand valuable information of ligand crystal structure, 
conformation and the orientation of the lead molecule, which provides the binding energy 
of the target receptor and finally the best-docked ligand structure. Thus, docking studies 
play a significant role in rational designing of drugs and aids the drug discovery process. 
 The anti-diabetic potential of M. charantia using structure-based screening of 
glycoalkaloids and related compounds against enzyme; aldose reductase was previously 
established. By taking ligands from 10 different medicinally important plants, the 
experiment was designed to understand the binding mechanisms of these ligands with 
aldose reductase protein (receptor) using XP docking program of Maestro, version 9.4, 
Schrödinger software. Synthetic drug metformin was used as a standard for comparison. 




diabetic activity compared to that of standard metformin. Isomers of vicine were also 
generated and docked with the receptor aldose reductase and found to have similar GLIDE 







CUCURBITANE-TYPE COMPOUNDS FROM MOMORDICA CHARANTIA: 
ISOLATION, IN VITRO ANTIDIABETIC AND ANTI-INFLAMMATORY 




Momordica charantia L., commonly known as bitter gourd or bitter melon, 
belongs to the Cucurbitaceae family. Various in vitro and in vivo studies have indicated 
that bitter melon extracts have anti-diabetic properties. However, relativity little is known 
about the specific bioactive compounds responsible for their antidiabetic properties. In the 
present study, three cucurbitane-type triterpene aglycones 3β,7β,25-trihydroxycucurbita-
5,23(E)-dien-19-al, charantal, and charantoside XI, and one sterol glucoside 25ξ-
isopropenylchole-5, 6-ene-3-O-D-glucopyranoside, were isolated from bitter melon fruit. 
The structure of each compound was elucidated by one and two-dimensional nuclear 
magnetic resonance, and HR-ESI-MS. The isolated compounds were evaluated for their 
anti-diabetic properties (inhibition of amylase and glucosidase enzymes) and anti-
inflammatory activities. All compounds exhibited significant in vitro inhibition of α-
                                                 
1 Reprinted with permission from “Cucurbitane-type compounds from Momordica 
charantia: Isolation, in vitro antidiabetic, anti-inflammatory activities and in silico 
modeling approaches” by Siddanagouda. R.S, Wilmer. H. Perera, Jose. L. Perez, Giridhar. 
Athrey, Yuxiang Sun, G.K. Jayaprakasha, B.S. Patil, 2019. Bioorganic Chemistry (2019), 




amylase and α-glucosidase, comparable to acarbose. Furthermore, computational 
molecular docking of all compounds showed molecular interactions with key amino acid 
residues in the catalytic sites of both enzymes, revealing their potential binding modes at 
the molecular level. Additionally, the purified compounds showed significant anti-
inflammatory activity, differentially downregulating the expression of NF-κB, INOS, IL-
6, IL-1β, TNF-α, and Cox-2 in murine macrophage RAW264.7 cells activated by 
lipopolysaccharide. Our findings suggest that these compounds purified from bitter melon 
have potential anti-diabetic and anti-inflammatory activities and therefore hold promise 
for the development of a plant-based management strategy for diabetic complications and 




Diabetes is a chronic metabolic disease, and its frequency has been rapidly 
increasing worldwide in recent years. 95 The incidence of type II diabetes is predicted to 
grow by 6% annually. Recent estimates report that by 2025, India, China, and the United 
States of America will have the most significant number of people with diabetes, 
compared with other countries. 96 Diabetes is a preventable, chronic disease that has a 
complex etiology and several strategies can be used for understanding and managing the 
disease. Once diabetes has developed, the next option is the management of 
hyperglycemia. Several synthetic drugs, including sulfonylureas (promote insulin 




(α-amylase and α-glucosidase inhibitors) can be used to manage post-prandial 
hyperglycemia. 95 For example, α-amylase, and α-glucosidase inhibitors reduce the levels 
of glucose in the bloodstream by reducing the rate of polysaccharide degradation. Despite 
significant developments over the last decade in treating Type II diabetes, numerous 
diabetic patients have been unable to reach their recommended therapeutic targets. 
Therefore, it is necessary to develop safe and bioactive natural anti-diabetic compounds 
that have fewer adverse effects than existing synthetic medications. 97 Bitter melon 
(Momordica charantia) extracts have been reported to inhibit the activities of α-amylase 
and α-glucosidase enzymes, but the bioactive component remains elusive. 
 Bitter melon (Momordica charantia)  is cultivated as a medicinal vegetable for 
the management of diabetes in tropical and subtropical areas including East Africa, Asia, 
South America, and the Caribbean. 98 Among various health benefits, the anti-diabetic 
activity of bitter melon has been related to various triterpenoids. In response to 
accumulating data correlating bitter melon and successful diabetes management, several 
preclinical and clinical trials have been conducted.  
Diabetes mellitus leads to hyperglycemic conditions, and like many other chronic 
diseases, inflammation is widely known to be a contributing factor. 99, 100 Subclinical 
chronic inflammation is a common feature in diabetes and associated with changes in 
levels of inflammatory biomarkers 101. The release of pro-inflammatory cytokines, such 
as interleukin-1β, IL-6, TNF-α, other inflammatory mediators like nitric oxide (NO), 
prostaglandins (PGE2), and the resulting activation of macrophages have a significant role 




inflammatory cytokines can amplify the inflammatory responses, leading to aggravation 
of diabetes and its long term complications including insulin resistance, age-related 
neurodegenerative disorders, and Alzheimer’s disease. 104 Recently, a few studies have 
explored the effect of bitter melon on inflammation, but the identification of the bioactive 
compounds responsible for this activity is still an active research topic. 105-107 
In this chapter, we present the isolation and structural elucidation of four 
compounds from an ethyl acetate extract of Chinese bitter melon. We evaluated the α-
amylase and α-glucosidase inhibitory activities of these purified compounds. Moreover, 
molecular docking allowed us to model the potential interactions of these compounds with 
the enzymes, to unveil the possible mechanism of inhibition. Additionally, purified bitter 
melon compounds were screened for their potential anti-inflammatory properties using 




3.3.1 Chemicals   
 
Silica-gel 60Å particle size (40–63 µm), glacial AcOH, phosphate-buffered saline 
(PBS), and RPMI-1640 were purchased from VWR International (Radnor, PA). The RAW 
264.7 mouse monocyte-macrophage cell line was procured from the American Type 
Culture Collection (ATCC, USA). Fetal bovine serum (FBS), penicillin, streptomycin, n-




grade), D-(+)glucose, dinitrosalicylic acid (DNSA), dextrose, sodium chloride, acarbose, 
and Porcine Pancreatic -amylase (PPA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Genes including GAPDH, Cox-2, TNF-α, IL-6, IL-1β, iNOS, NF-κB and the Aurum 
Total RNA Mini Kit, iScript cDNA synthesis kit, and SsoAdvanced Universal SYBR 
Green Supermix were purchased from Bio-Rad Laboratories (Hercules, CA). Silica gel 60 
F254 thin-layer chromatography plates, HCl, and H3PO4 were purchased from EMD 
Millipore, Burlington, MA). RP-C18 cosmosil 140 was purchased from Nacalai Tesque, 
Inc, (Kyoto, Japan). Flash silica gel cartridges (RediSef ®Rf) were procured from Teledyne 
ISCO, Lincoln, NE. Perdeuterated MeOH, CHCl3, and pyridine were purchased from 
Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA). Nano-pure water (18.2 
M-cm) was obtained from a NANO pure purification system (Barnstead/ Thermolyne, 
Dubuque, IA). 
 
3.3.2 General experimental procedure  
 
Flash chromatography system Teledyne ISCO CombiFlash Rf 4x system equipped 
with a fiber optic spectrometer, a UV-vis (λ 200–700 nm) detector, was used for the 
purification. Individual fractions were collected and analyzed using an Agilent 1200 Series 
HPLC (Agilent, Foster City, CA) system consisting of a degasser, quaternary pump, 
autosampler, column oven, and a diode array detector. The separation was carried out 
using an RP C-18 Gemini series column (250 ×4.6 mm; 5 µm) (Phenomenex, Torrence, 




chromatograms were recorded at 210, 280, and 320 nm. The elution was carried out using 
gradient mode elution with 3 mM phosphoric acid (A) and acetonitrile (B). Initially, 
elution was carried out in isocratic 20% B for 2 min, followed by 20–50% B (2–6 min), 
50–90% B (7–10 min), and 90–95% B (11–18 min) followed by isocratic 95% B up to 23 
min and returned to 20% B (24–26 min). The column was equilibrated for 2 min before 
the next injection. UPLC-HRESIMS were acquired using a maXis impact mass 
spectrometer (Bruker Daltonics, Billerica, MA) coupled to a 1290 Agilent LC (Agilent, 
Santa Clara, CA) using a quadrupole time of flight mass detector equipped with an 
electrospray ionization interface controlled by Bruker software (Bruker Compass Data 
Analysis Version 4.2). Data acquisition and processing were done using the Bruker 
software (Bruker Compass Data Analysis Version 4.2). The NMR spectra 1D (1H; 13C and 
DEPT 135) and 2D NMR spectra were recorded with a JEOL spectrometer (USA, Inc., 
Peabody, MA) at 25°C, operating at 400 MHz (1H) and 100 MHz (13C) using 
standard JEOL pulse programs. The chemical shifts are given in δ (ppm) and were 
referenced to residual solvent signals. Samples were dissolved based on their solubility in 
methanol-d4, pyridine-d5, and CHCl3-d. Optical rotations were measured on a ATAGO 
SAC -i polarimeter in MeOH at 21.8°C. 
 
3.3.3 Extraction  
 
Fresh fruits of Chinese bitter melon (136 kg) were purchased from a local market 




pieces, then the seed and fruit parts were separated and air dried. Dried samples of Chinese 
bitter melon were blended using a Vita-prep™ blender to 40–60 mesh size powder (Vita-
Mix Corporation, Cleveland, OH). Total fruit powder (5.6 kg) was defatted using n-hexane 
and extracted using ethyl acetate using a Soxhlet apparatus at 60–70°C for 32 h.  Extracts 
were concentrated under reduced pressure using rotary evaporator (Buchi, New Castle, 
DE), freeze-dried and stored at -80°C for further use. The EtOAc extract of 33.8g (dry 
weight) was used for further experiments. 
 
3.3.4 Fractionation of the crude ethyl acetate extract  
 
The ethyl acetate crude (EtOAc) extract (103.7 g) was impregnated with 40 g of 
silica gel and chromatographed over silica gel (2.5 kg silica-gel 60 Å 40–63 µm) column 
chromatography. Initially, the column was eluted with n-hexane, n-hexane/EtOAc (95:5, 
90:10, 85:15, 80:20, 60:40, 50:50, 40:60, 25:75, and 0:100 v/v) and a similar step gradient 
with EtOAc/acetone, acetone/MeOH and finally with MeOH to give 40 fractions of 300 
ml each. Fractions were concentrated under reduced pressure using a rotary evaporator 
and pooled based on TLC chromatographic profile.  
 
3.3.5 Purification  
 
Fraction 20 (600 mg) was impregnated with 200 mg silica gel and air-dried in a 




was subjected to flash chromatography in a 120 g silica gel cartridge, at 60 ml/min over 
60 min, eluted using a gradient program with n-hexane and EtOAc from 100–0% with 
increasing polarity of eluents. In total, 210 fractions, 3.15 l (210×15 ml each) were 
collected, and fractions were pooled based on silica gel TLC profiles to give subfractions 
1–17. Fractions 13 and 16 were crystallized in a test tube to yield compound 1 (15 mg), 
and fraction 16 yielded compound 2 (9 mg). Similarly, pools 25–30 of 1738 mg from 
chromatography 1 were subjected to flash chromatography using RP-Cosmosil 140 C18 
column of 43 g using H2O: MeOH (100–0%, 60 ml/min flow rate) linear gradient to afford 
82 fractions, 1230 ml (82×15 ml each). Collected fractions were pooled based on HPLC 
Retention Time. Fractions 16–23, RT 14.2 min, H2O: MeOH (15:85) were pooled to yield 
compound 3 (24.4 mg). Similarly, fractions 35–40 (1263 mg) from chromatography 1 
were subjected to flash chromatography in a 120 g silica gel cartridge with a 90-min 
gradient program, flow rate of 85 ml/min of solvent A1 (ethyl acetate): B1(acetone) 
gradient elution of 100–0% to give 113 fractions of 15 mL each. Fractions (84–92) 
(EtOAc: acetone 7:3) yielded compound 4 (24.9 mg). 
 
3.3.6 Inhibition of -amylase assay  
 
-Amylase inhibitory activity was determined using a published protocol with 
minor modifications. 108 All four compounds were prepared to 10 mM in 500 l DMSO 
and used for the inhibition of α-amylase assay. Two concentrations of 10 and 20 µl 




was conducted in triplicate. The acarbose (10 and 20 µl equivalent to 0.067 and 0.13 mM) 
was used as a positive control. The absorbance was measured at 540 nm in a KC-4 
microplate reader (BioTek Instruments, Inc., Winooski, VT) and % inhibition was 
calculated according to the published method. 
 
3.3.7 Inhibition of -glucosidase assay 
 
The 𝛼-Glucosidase activity of purified compounds was determined according to 
the method with slight modifications, using 𝛼-glucosidase from S. cerevisiae. 109 Acarbose 
was used as a standard in this experiment. The 𝛼-glucosidase activity was determined by 
measuring the yellow-colored para-nitrophenol released from pNPG at 405 nm. The 
absorbance was measured at 405 nm in a KC-4 microplate reader (BioTek Instruments, 
Inc., Winooski, VT, USA). Percentage inhibition was calculated as %Inhibition = (Abs 
control –Abs test) X100/ Abs control. 
 
3.3.8 In silico molecular docking of purified compounds against -amylase and -
glucosidase 
 
Mode of inhibition of compounds 1–4 on the Porcine Pancreatic α-amylase (PPA) 






3.3.8.1 Preparation of protein and ligand structure 
 
The 3-D coordinates of the crystal structures of proteins were downloaded from 
the RCSB protein data bank (PDB, http://www.rcsb.org/pdb) in PDB format. Porcine 
Pancreatic -amylase complexed with acarbose (PDB ID: 1OSE) was downloaded from 
the PDB. The complexed acarbose was removed using Biovia Discovery studio 4.5 (DS 
4.5, Dassault Systems BIOVIA, Discovery Studio Modeling Environment, Release 4.5, 
San Diego. 2015). Similarly, for -glucosidase, the crystal structure (PDB ID:3A4A) of 
isomaltase from S. cerevisiae was downloaded from the PDB. Later, both proteins were 
prepared by removing all water molecules, and a CHARMm force field was applied 
using the Receptor-Ligand interactions tool in DS. Further, binding of acarbose to 1OSE 
and active residues of the crystal structure of isomaltase were identified using the 
Computer Atlas of Topography of Proteins (CASTp), a program for identifying and 
characterizing active protein sites, binding sites, and functional residues located on the 
protein surface. The discovery studio tool was used to convert this file into the PDB 
format. Two-dimensional structures of purified compounds were drawn using ChemDraw 
tool (PerkinElmer Informatics, 2016) and saved as a molecular format file (MDL MOL 
format). The “Prepare ligand” protocol of DS 4.5 was used to prepare the ligands which 
remove duplicate structures, standardizes the charges of common groups, calculates the 
ions and ionization of the ligand's functional groups, 2D-3D conversion, verifying and 
optimizing the structures, and other tasks established by user-defined parameters. All the 




3.3.8.2 Molecular docking using Autodock 4.2 
 
The four ligands were docked with -amylase and -glucosidase using the 
Lamarckian genetic algorithm (LGA) provided by the AutoDock Program (ADT, version: 
1.5.6) version 4.2. Polar hydrogens were added to the receptor, Kollman charges were 
assigned, and solvation parameters were added with the “Addsol” option in AutoDock. 
For the inhibitors, charges of the Gasteiger type were assigned. The internal degree of 
freedom and torsion were defined using the “Ligand Torsions” menu option of AutoDock. 
The grid maps representing the protein were calculated using the “AutoGrid” option. The 
protein was centered on the geometric center before docking, and the dimensions of the 
cubic grid box were set to 126 Å of x, y, and z with a spacing of 0.375 Å for both proteins. 
Blind Docking was carried over the whole receptors (i.e., 1OSE and 3A4A) using Genetic 
Algorithm.  The best ligand-receptor structure from the docked structures was chosen 
based on the lowest energy and minimal solvent accessibility of the ligand. The 2D 
visualization of ligand interactions with the protein domain was analyzed using DS4.5, 
and PyMOL molecular graphics system (PyMOL Molecular Graphics System, San Carlos, 
CA, USA) was used to visualize the 3D interactions between ligands and receptors better.  
 
3.3.9 Cell culture and maintenance 
 
The RAW 264.7 mouse monocyte-macrophage cell line was procured from 




supplemented with 10% (v/v) fetal bovine serum and antibiotics (100 U/ml penicillin and 
100 μg/ml streptomycin). Cells were incubated at 37°C in a humidified incubator with 5% 
CO2. The media was changed every 48 h and cells that reached 80% confluence were used 
for further experiments. 
 
3.3.9.1 RNA isolation and quantitative real-time polymerase chain reaction (qRT-
PCR) 
 
RAW 264.7 cells were seeded into 6-well plates at a density of 5.0×105 cells/well. 
Cells were incubated at 37°C and 5% CO2 for 24 h. Following incubation, the cells were 
treated with 25 μM of purified compounds (1–4) for 1 h. After 1 h, LPS (1 µg/ml) was 
added to specified wells, and the cells were incubated for an additional 18 h. Following 
the incubation period, total RNA was extracted using the Aurum Total RNA Mini Kit. 
RNA concentrations were determined using a Nanodrop Spectrophotometer (Thermo 
Scientific NanoDrop Products). Purified RNA from cell lysate was used to synthesize 
cDNA according to the manufacturer’s manual (iScript cDNA Synthesis Kit, Bio-Rad). 
Real-time PCR was performed on a Bio-Rad using the SYBR Green PCR Master Mix, 
according to the protocol provided by the manufacturer and relative expression was 







3.3.10 Statistical analysis  
 
Statistical analysis was performed using JMP Pro14 (SAS, NC, U.S.A.) statistical 
software. All data were expressed as mean ± SD. All statistical comparison compared 
through one-way analysis of variance (ANOVA), using Tukey’s HSD post hoc test (p < 
0.01, n=3). 
 
3.4 Results and discussion  
 
3.4.1 Structural elucidation of compounds   
 
An ethyl acetate extract from Chinese bitter melon fruit was subjected to silica gel 
and reverse-phase flash chromatography to separate one new cucurbitane-type triterpene 
(compound 3) together with two known triterpene aglycones (compounds 1 and 2), and 
one sterol glucoside (compound 4). Compounds 1, 2, and 4 were characterized by 1-D and 
2-D NMR and high-resolution mass spectroscopy data (Table 3 and Figure A1–A8). 
Compounds 1 and 2 were identified as 3, 7, 25-trihydroxycucurbita-5, 23(E)-dien-19-
al (TCD) and charantal, respectively. The chemical shifts of these compounds were 
matched to reported data. 110, 111 Previously, TCD and charantal were isolated from leaf 
extracts of M. charantia, and this is the first report of their isolation from fruit. Compound 
4 was previously isolated from the fresh fruit of M. chrantia and was identified as 25ξ-




Compound 3 was purified as a white amorphous powder, [α]25D -24.16 (c 0.1, 
MeOH). HR-ESIMS of compound 3 showed a molecular ion at m/z 523.34233 [M+Na]+ 
(calculated m/z 523.3399 [M+Na]+) suggesting a molecular formula of C31H48O5Na. The 
molecular weight of compound 3 was compared with our in-house database of all 
triterpenes and sterols isolated from M. charantia until 2018.  
The 13C Attached proton test (APT) NMR data of compound 3 (Figure 2) showed 
31 carbons with six methines (including one oxymethine group), seven methylenes, seven 
methyl groups, five quaternary carbons, one aldehyde, one carboxylic acid, and four 
olefinic carbons, one tri-substituted and three di-substituted. The complete assignment of 
Heteronuclear Multiple Quantum Coherence (HMQC) correlations is shown in 
Supplementary Figure A9 and Table A1. The lack of olefinic carbons in kuguacin C, the 
presence of two tri-substituted olefinic carbons, and the absence of methoxy groups in the 
purified compound 3 suggested its structural novelty. Six tertiary groups appeared at 
δH(δc) 0.9 (15.5), 1.25 (30.3), 1.25 (30.2), 1.17 (27.5), 1.21 (25.6), and 0.82 (18.8) ppm 
corresponding to methyl groups at positions 18, 26, 27, 28, 29, and 30, respectively, and 
one secondary at 0.95 (19.3) ppm (d, J= 5.8 Hz) corresponding to a methyl group at  
position 21. Positions of the methyl groups were assigned through Heteronuclear Multiple 




Table 3 1H and 13C NMR data for purified compounds 1, 2, and 4 from the EtOAc extract of Momordica 
charantia 
  Compound 1 (CDCl3) Compound 2 (CD3OD) Compound 4 (pyridine-d5) 
Position δH (ppm) δC (ppm) δH (ppm) δC 
(ppm) 
δH (ppm) δC 
(ppm) 
1 1.76; 1.54 21.4 1.31, m; 1.21, m 35.8 1.00, m; 1.77, m 37.66 
2 1.95; 1.90 28.6 1.82, m; 1.31, m 28.7 2.12, m; 2.18, m 30.27 
3 3.55 (1H, m) 76.3 3.46 br, s 77.2 3.99, m 78.84 
4 - 41.6 - 42.4 2.49, m; 2.77, m 39.46 
5 - 145.7 - 147.5 - 140.84 
6 5.88 (1H, br d, J=3.9 
Hz 
124.2 5.81 (1H, dd, J=1.7, 
5.3 Hz) 
124 5.37 (br s) 122.2 
7 3.95 (1H, br d, J=4.7 
Hz) 
66.5 3.92 (d, J=5.2 Hz) 67 1.90, m; 1.95, m 32.36 
8 2.07 m 47.8 2.45 (1H, m) 37.8 1.4, m 32.23 
9 - 50.1 1.83 51 0.92, m 50.36 
10 2.51 (1H, br dd 
J=12.0; 4.0 Hz) 
36.8 - 46.7 - 37.1 
11 2.21; 1.57 m 23.8 1.53, m; 1.40, m 22.3 1.38, m; 1.48, m 21.47 
12 1.93; 1.39 m 27.6 1.79, m; 1.66, m 29.7 1.12, m; 2.02, m 39.98 
13 - 45.5 - 45.3 - 42.5 
14 - 47.8 - 51.4 1.01, m 56.86 
15 1.37; 1.37 m 34.9 1.36, m; 1.32, m 23.4 1.55, m; 1.55, m 24.67 
16 1.68; 1.68 m 29.2 1.66, m; 1.56, m 29.96 1.30, m; 1.84, m 28.65 
17 1.49 m 50.1 1.45 (1H, m) 51.2 1.06, m 56.28 
18 0.87 (3H, s) 15.1 0.81 (3H, s) 15.5 0.69 (3H, s) 12.15 
19 9.71 (1H, s) 208.5 0.71 (3H, s) 18.9 0.95 (3H, s) 19.61 
20 1.49 36.4 1.45 (1H, m) 37.7 1.44, m 35.94 
21 0.89 (3H, s) 18.9 0.84 (3H, d, J=5.8 
Hz 
19.3 0.88 (3H, d, J=6.3 
Hz 
19.1 
22 2.12; 1.71 39.3 2.05; 1.71 (2H, 
m,m) 
40.4 1.07, m; 1.41, m 34.15 
23 5.57 (1H, m) 125.3 5.48 (1H, m) 126 
 
30.45 
24 5.55 (1H, d, J=14.4 
Hz 
139.9 5.48 (1H, d, J=6.34 
Hz) 
141 1.27, m; 1.83, m 29.83 
25 - 70.9 - 71.4 1.94, m 49.85 
26 1.29 (3H, s) 30.2 1.16 (3H, s) 29.98 1.39, m; 1.39, m 26.95 
27 1.29 (3H, s) 30.1 1.16 (3H, s) 29.87 0.87 (3H, t, J=7.8 
Hz 
12.51 
28 1.04 (3H, s) 27.4 0.98 (3H, s) 27.9 - 147.81 
29 1.23 (3H, s) 25.6 1.15 (3H, s) 26.3 4.83, m; 4.90, m 112.21 
30 0.73 (3H, s) 18.1 9.78 (1H, s) 210.1 1.64 (3H, s) 18.01 
Glu-1' 
    
5.06 (d, J=7.3 Hz) 102.69 
Glu-2' 
    
3.99, m 75.47 
Glu-3' 
    




    
4.31, m 71.4 
Glu-5' 






4.32 (dd, J=2.2, 
11.7 Hz); 4.48 






The side chain of compound 3 was identified through HMBC correlations of 71.3 
ppm (C-25) with the methyl groups at position 26 and 27 (1.25 ppm, s, 6H), and with 
olefinic protons at 5.58 ppm. Additionally, COSY correlations between 5.58 ppm with 
2.16 and 1.78 ppm (CH2 at C-22) were also observed. The side chain -CH(CH3) 
CH2CH=CH-C(CH3)2 of compound 3 was similar to those previously reported for 
kuguacin A and S, and momordicine VII. 113 54 The 3J HMBC correlation of the 
oxymethine proton at 4.82 ppm with the tri-substituted olefinic carbon at 146.5 ppm 
suggested a C-5 and C-6 double bond. 3J HMBC correlation of the methine proton at 2.65 
ppm (J = 13.2 and 4.3 Hz) characteristic of H-10 with 124.2 ppm together with the COSY 
and HMBC correlations of the olefinic proton at 5.93 ppm with the oxymethine proton at 
4.03 ppm and with the methine carbon at 51.3 ppm at C-8, respectively, corroborated the 
double bond position and the oxymethine group at C-7. The aldehyde group was found to 
be in position C-19 attached at C-9 (51.2 ppm), and the carboxylic acid at C-3 evidenced 
through 3J HMBC correlations of the aldehyde carbon with protons H-8 and H-10 and 
carboxylic acid group with 4.82 ppm at C-3. This is the first report of a cucurbitane-type 
triterpene containing a carboxylic acid; hence compound 3 was identified and named 
charantoside XI. The complete 2D NMR of compound 3 are shown in Figure A10-A13. 





Figure 2 Complete assignments of HMBC spectra of compound 3 (charantoside XI). Spectra were recorded in MeOH-d4.1HNMR on X-axis and 13C 






Figure 3 Structures of identified compounds (1–4) from the EtOAc extract of Momordica charantia and 




3.4.2 Inhibition of -amylase and -glucosidase activity 
 
The inhibitory effect of purified compounds on -amylase and -glucosidase at 
two concentrations were tested and results were compared with acarbose (Figure 4A). 
Compounds 1-4 showed inhibition of 44-61% and 63-79% of -amylase at 0.43 mM and 
0.87 mM concentrations respectively. Acarbose exhibited significantly higher inhibitory 
activity (88%) at 0.13 mM. Among the isolated compounds, IDG showed the highest 
inhibitory activity (79%) followed by charantal (70%) and TCD (69%) against -amylase 
at 0.87 mM concentration. The novel compound, charantoside XI, showed moderate 
inhibition of 62% against -amylase.  
Similarly, inhibition of α-glucosidase was evaluated at 0.67 mM, and 1.33 mM 
concentrations and results were compared with positive control acarbose at 0.06 and 0.13 
mM (Figure 4B).  Maximum of 81.9% inhibition was observed for acarbose at 0.13 mM, 
followed by IDG (71%), TCD (65%), charantal (60%) and charantoside XI (5%) at 1.33 
mM. The inhibitory activity of compounds 1–4 may be due to their differences in structural 
configuration.  Nevertheless, TCD has been demonstrated for reducing the blood glucose 
level in diabetes-induced male ddY mice and showed moderate anti-HIV activity with 
EC50 value of 25.62 µg/mL. 54, 114 In the present study, TCD showed good inhibitory 
activity against the two enzymes. Also, IDG showed significantly higher inhibition 
compared to the other compounds and comparable activity to that of acarbose. The 
suppression of salivary, pancreatic α-amylase and α-glucosidase in the brush border 




turn controls the blood glucose 115. The inhibitory mechanism of these compounds may be 
due to conformational changes derived from the presence of a sugar moiety in IDG, 
possibly allowing the binding of IDG to these enzymes.  A higher number of attachments 
of sugar moieties would be needed to further evaluate the influence of cucurbitane 
glycosides on the inhibition of these enzymes. 
 
3.4.3 Molecular docking 
 
3.4.3.1 Virtual molecular docking study for inhibition of α-amylase by the purified 
compounds 
 
In order to predict the mode of interactions of compounds 1–4 with -amylase, 
molecular docking was carried out using Autodock 4.2. The enzyme -amylase is 
composed of A, B, and C domains. Domain A is the largest with residues 1–99 and 169–
404. Domain A forms a central eight-stranded parallel β-barrel with active site residues 
Asp197, Glu233, and Asp300. Domain B is the smallest (residues 100–168) and forms a 
calcium binding site against the wall of the β-barrel of domain A. Protein groups making 
ligand interactions with this calcium include Asn100, Arg158, Asp167, and His201. 
Domain C (residues 405–496) is made up of an antiparallel β-structure and is loosely 
associated with domains A and B. 116 The refined -amylase structure is well characterized 
and has a network of water molecules occupying the cleft of the active site and hydrogen-




Asn298, and with the main chain through Ala307 N and Trp59. Also, the binding cleft is 
characterized by aromatic residues such as Trp58, Trp59, Tyr62, His101, Pro163, Ile235, 




Figure 4 Effect of purified compounds on the inhibition of (A). α-amylase and (B). α-glucosidase, 
acarbose was used as a positive control and all the experiments were conducted in triplicate with two 
biological replications. The results are represented as means ± SD for (n=6). Identical letters at each 
concentration are not significantly different at p ≤ 0.001. Abbreviations, TCD: (3β,7β,25-












































































Asp300 are close together in the active site of -amylase and are known as the binding 
cleft, which lies in a deep depression at the center of -amylase.  118 
The results of the 2D and 3D molecular docking images of compounds 1–4 are 
shown in Figure 5A–5D. The 2D schematic ligand-protein complex images are shown in 
Fig. S9. All compounds were anchored to the catalytic site of -amylase through various 
bonds. Table 4 summarizes the binding affinity and binding interactions of purified 
compounds 1–4 with porcine pancreatic α-amylase (PDB ID: 1OSE). As shown in Figure 
5A, the refined docking of TCD generated the best pose with a minimum binding energy 
of -10.55 kcal/mol. The 2D schematic Figure A14A and 3D diagram (Figure 5A) 
illustrate TCD inserted into the cavity of -amylase. TCD interacted with amino acid 
residues Glu233, Ile235, Lys200, Tyr151, Gly306, His305, Trp59, Trp58, Val163, and 
Leu162 in domain A of -amylase. Five conventional hydrogen bonds were found 
between TCD and amino acid residues (Glu233, Ile235, Tyr151, Gly306, and His305) 
with bond lengths of 4.02, 3.45, 6.84, 3.85, and 4.06 Å, respectively. These hydrogen 
bonds strengthened the interactions between TCD and -amylase. The interactions of 
TCD include alkyl and pi-alkyl interactions between Trp59, Trp58, Val163, and Leu162.  
Similarly, charantal bound to the active site of -amylase with a binding energy -
8.76 kcal/mol. As shown in Figure 5B and Figure A14B, charantal interacted with crucial 
amino acid residues including Trp58, His305, Trp59, Val163, Leu162, Lys200, His201, 
Ile235, and Glu240 in domain A of -amylase. Hydroxyl groups at position C-3 and C-25 





Figure 5 The 3D ligand-protein interactions for (A). 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al, (B). 
charantal, (C). charantoside XI, and (D). 25ξ-isopropenylchole-5, (6)-ene-3-O-β-D-glucopyranoside, in the 





and Glu240 with a bond length of 4.47 and 4.81 Å, respectively. We also observed pi-
alkyl and alkyl interactions of charantal with several amino acid residues including 
Trp58, His305, Val163, Leu162, Lys200, His201, and Ile235 with bond lengths of 5.30, 
5.25, 5.14, 4.69, 4.35, 5.85, and 4.08 Å respectively.  
The refined docking of charantoside XI with -amylase generated the best pose 
with a minimum binding energy of -9.79 kcal/mol. The 3D schematic in Figure 5C shows 
that charantoside XI established several hydrogen bonds within the -amylase enzymatic 
pocket and interacted with several amino acid residues, including Glu233, Gly306, Trp59, 
Gln63, Trp58, His305, Val163, Leu162, and Ile235 (Figure A14C). Four conventional 
hydrogen bonds were established between charantoside XI and the active pocket of -
amylase, in which the carboxylic acid at position 3 formed H-bonds with Trp59 and Gly63 
with a bond length of 4.23 and 4.29 Å, respectively. Similarly, hydroxyl groups at C-25 
and the CHO group at C-19 position established hydrogen bonding with Glu233 and 
Gly306 with a bond length 3.26 and 3.75 Å, respectively. Charantoside XI also established 
pi-alkyl and alkyl interactions with Ile235, Leu162, Val163, His 305, Trp 58 with bond 
lengths of 4.69, 5.25, 5.76, and 5.78 Å, respectively. 
Figure 5D displays a 2-D schematic interaction of IDG with -amylase. IDG 
generated the best docking pose with a minimum binding energy of -11.98 kcal/mol, 
which indicates that IDG showed the strongest binding affinity with the -amylase 
protein. The strong binding affinity may be related to IDG’s high α-amylase inhibitory 




amylase by making conventional hydrogen bonds to residues Gly306, Glu240, and Gly306 
resulting in a potent inhibition of -amylase. 
 
3.4.2.2 Virtual molecular docking study for inhibition of α-glucosidase by the purified 
compounds 
 
Similarly, to elucidate how the purified compounds interact with α-glucosidase, 
molecular docking analysis was carried out to investigate the binding mode of compounds 
within the binding pocket of α-glucosidase. To date, the crystal structure of α-glucosidase 
from Saccharomyces cerevisiae (the enzyme used for the biological assay) has not been 
resolved. Therefore, the compounds were docked to isomaltase crystal structure 3A4A 
downloaded from the Protein Data Bank. Isomaltase from S. cerevisiae co-crystallized 
with maltose has 85% similarity to yeast α-glucosidase (MAL12) through homology 
modeling 101. Asp69, His112, Arg213, Asp215, Glu276, His351, Asp352, and Arg442 are 
key residues in the active catalytic site of α-glucosidase. 119 Table 2 summarizes the 
binding affinity and binding interactions of purified compounds 1–4 with the crystal 
structure of isomaltase from S. cerevisiae. 
Table 2 lists the binding energy of TCD, charantal, charantoside XI, and IDG with 
interacting residues, including H-bond interacting residues and Van der Waals interacting 
residues, along with the number of H-bonds. The 2D schematic and 3D interactions of 
TCD are shown in Figure 6A and Figure A15A. TCD interacted with crucial amino acid 




Asp242, and Tyr158.  According to the Autodock 4.2 simulation results, the α-
glucosidase–TCD inhibitor complex showed -10.87 kcal/mol binding energy. TCD made 
five hydrogen bonds with interacting residues Lys156, Ser241, and Asp305, and two 
hydrogen bonds with His 208. The hydroxyl group at position 25 established two hydrogen 
bonds with Lys156 and Ser241 with bond lengths of 4.34 and 3.97 Å, respectively. 
Similarly, the hydroxyl group at position 7 of TCD established two hydrogen bonds with 
His280 with bond lengths of 4.26, 5.38 Å.   The aldehyde group at position 19 was able to 
establish a hydrogen bond with Asp 307 with a bond length of 5.74 Å. Moreover, the 
hydroxyl group at position 3 formed Van der Waals interaction with Arg442 with a bond 
length of 3.98 Å, which is critical interaction to inhibit enzyme to a greater extent.  
Charantal had binding energy of -10.78 kcal/mol and occupied the active region of 
isomaltase by interacting with amino acid residues Lys156, Phe303, Gly353, Glu411, 
Arg315, Tyr158, and Ser240. The 2D schematic (Figure A15B) and 3D interactions of 
charantal are shown in Figure 6B. In the conformation of isomaltase–charantal complex, 
the three hydroxyl groups at position 3, 7, and 25 of the ligands formed hydrogen bonds 
with the amino acid residues Lys156, Gln353, and Glu411 with bond lengths of 4.14, 4.53, 
and 4.61 Å, respectively. These hydrogen bonds overtly strengthened the interaction 
between charantal and isomaltase. Methyl and aldehyde groups at position 18 and 19 
established strong Van der Waals bonding with amino acid residues Arg315 and Ser240 
with bond lengths of 4.32 and 3.40 Å, respectively. The above interactions resulted in an 





Table 4 Binding affinity and binding interactions of purified compound (1–4) with porcine pancreatic α-amylase (PDB ID: 1OSE) and α-glucosidase 
(PDB ID: 3A4A) 
 
 











TCD -10.55 5 Glu 233, Ile 235, Tyr 151, Gly 306, 
His 305, Trp 59, Trp 58, Val 163, Leu 
162 
Ile 235 (3.45 Å), Glu 233 (3.45 
Å), Tyr 151 (6.84 Å), Gly 306 
(3.85 Å), His 305 (4.06 Å) 
18.53 
Charantal -8.76 2 Trp 59, His 305, Trp 58, Ile 235, Lys 
200, His 201, Leu 162, Val 163, Tyr 
62 





-9.79 4 Glu 233, Gly 306, Gly 63, Trp 59, 
Gly 306, His 305, Val 163, Leu 162, 
Ile 235 
Glu 233 (3.26 Å), Gly 306(3.75 
Å), Trp 59 (4.29 Å), Gly 63 
(4.23 Å) 
66.39 
IDG -11.98 4 Trp 59, Trp 58, His 305, Tyr 62, Leu 
162, Ala 198, Gly 306, Glu 240 Lys 
200, Ile 235, His 201, Leu 165, Val 
163 
Glu 240(4.81 Å), Trp 59 (4.47 







TCD -10.87 5 Lys 156, Ser 241, Asp 307, Arg 315, 
Phe 303, Arg 442, His 280, Asp 242, 
Tyr 158 
Lys 156 (4.34 Å), Ser 241 (3.97 
Å), Asp (4.26 Å),  
His 280 (5.38 and 5.74 Å) 
10.68 
Charantal -10.78 3 Ser 240, Lys 156, Phe 303, Gly 353, 
Glu 411, Arg 315, Tyr 158, Ser 240 
Lys 156 (4.14 Å), Glu 411 




-10.4 4 Phe 314, Leu 313, Arg 315, Phe 159, 
Asp 69, Arg 442, Tyr 158, Phe 303, 
Phe 314 
Leu 313 (5.10 Å), Asp 307 
(5.00 Å), Asp 69 (4.60 Å), Arg 
442(6.42 Å)   
23.86 
IDG -10.58 3  Leu 313, Asp 242, Pro 312, Val 308, 
Val 319, and His 280 
Leu 313 (4.98 and 3.94 Å), Asp 







Figure 6 The 3D ligand-protein interactions for (A). 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al, (B). 
charantal, (C). charantoside XI and (D). 25ξ-isopropenylchole-5, (6)-ene-3-O-β-D-glucopyranoside, in the 
binding pocket of α-glucosidase. The ligands in the 3D structure are shown in green and hydrogen bonds 




Figure 6C and Figure A15C shows the binding mode of charantoside XI in the 
active site of isomaltase. The ligand was stabilized in the active site of an enzyme by 
interacting with amino acid residues Phe314, Leu313, Arg315, Phe159, Asp 69, Arg442, 
Tyr158, Phe303, and Phe314. The carboxylic acid group at position 3, hydroxyl groups at 
positions 7 and 25, and the aldehyde group at position 19 formed five conventional 
hydrogen bonds with Asp307, Leu313, Arg315, Asp69, and Arg442 with bond lengths of 
5.10, 5.00, 5.48, 4.60, and 6.42 Å, respectively. The interaction between the ligand and 
the catalytic residue Arg 442 was essential for the inhibition of isomaltase. The methyl 
groups at positions 18, 29, and 21 formed pi-alkyl interactions with amino acid residues 
Tyr58, Phe59, and Phe314. Finally, the binding energy was -10.4 kcal/mol and the 
inhibition constant was 23.86 nM. 
IDG bound to residues Leu313, Asp242, Pro312, Val308, Val319, and His280 at 
the catalytic site of isomaltase. The 2D schematic and 3D interactions of IDG are shown 
in Fig. 5D. IDG generated the best docking pose with a minimum binding energy of -10.58 
kcal/mol. The ligand was surrounded by catalytic residue Asp242, and the interaction was 
likely crucial for inhibition of the isomaltase. Three conventional hydrogen bonds were 
formed in which C-2’ and C-3’ on the sugar moiety formed H-bonds with Leu313 (3.94 
and 4.98 Å) and Asp242 (5.16 Å). These hydrogen bonds strengthened the interactions 
between IDG and α-glucosidase. IDG formed pi-alkyl and alkyl interactions between 






3.4.4 Gene expression  
 
Four purified compounds from bitter melon were tested for anti-inflammatory 
activity in LPS-activated RAW 264.7 macrophages. All of the compounds tested 
differentially affect the expression of   NF-κB, iNOS, IL-6, IL-1β, and Cox-2 except TNF-
α, which was not significantly different from the LPS control group regardless of the 
treatment (Figure 7). A significant decrease in expression of NF-κB, iNOS, IL-1β, and 
Cox-2 was observed in the TCD treatment group when compared to the LPS control group.  
Similar results were observed in the cells treated with charantoside XI and IDG, except 
NF-κB displaying levels similar to the LPS control group.  The expression of iNOS, IL-
1β, and Cox-2 was significantly lower compared to the LPS group, while the expression 
of NF-κB was not affected in the charantal treatment group. Surprisingly, the level of IL-
6 dramatically increased in response to treatment of cells with charantal. TCD, charantal, 
and charantoside XI are structurally similar; however, they differ in the position of the 
aldehyde and carboxylic acid groups, which may be responsible for their anti-
inflammatory activity. TCD and charantoside XI have an aldehyde group at position 19 
and both significantly down-regulated the expression of NF-κB, iNOS, IL-1β, COX-2 
compared to the LPS-treated control at 25 µM concentration. Charantal has an aldehyde 
group at position 30, and it was not observed to be significantly different from the LPS-
activated cells for NF-κB and TNF-α. In charantoside XI, the presence of a carboxylic acid 
group at position 3 showed significant suppression of pro-inflammatory cytokines iNOS, 




of pro-inflammatory cytokines NF-κB, IL-6, and TNF-α. However, IDG treatment did 
downregulate iNOS, IL-1β and Cox-2 compared to the LPS control group. IDG has a 
glucose moiety in position 3, while the other tested compounds have a hydroxyl or 
carboxylic acid group in that position. It is widely accepted that slight variation in the 
chemical structures of bioactive compounds can influence its activity. Our results show 
that regardless of the similarities of the triterpenoid nucleus, slight structural differences 
influence the expression of gene correlated to the regulation of the inflammatory response 
in RAW 264.7 macrophages.   
Several triterpenoids have been isolated from various plants and evaluated for their 
bioactive potential. 120, 121 The structure-function activities of this class of compounds 
fluctuate in response to modifications to the 3 position. 122 In this study we observed that 
the glucose molecule attached to position 3 did not counteract the effect of LPS in inducing 
the expression of NF-κB, IL-6, and TNF-α and for the most part the effect of gene 
expression was not as pronounced at the other treatment compounds. Previous reports 
evaluating the bioactivity of triterpenoids have concluded that an increase in a number of 
glucose molecules or differences in its attached position may alter the compound’s 
bioactivity by steric hindrance. Additionally, the change the number and position of 
hydroxyl groups may alter its polarity and in turn its interaction with membrane 
phospholipids, resulting in altered bioactivities. 123 Therefore, it is crucial to elucidate the 
composition of bitter melon metabolites further to understand better how these compounds 
may be used as beneficial treatments for the management of diabetes and other 




assessment of the anti-inflammatory properties of these compounds, this screening 
procedure is useful possibly narrowing down potential targets for further studies. For 
example, NF-κB is a significant component of the signaling cascade that lead to an 
inflammatory response resulting in the production of inflammatory cytokinins such as 






Figure 7 Effect of purified compounds on m-RNA expression of NF-κB, INOS, IL-1β, IL-6, Cox-2 and 
TNF-α in LPS induced murine macrophage RAW 264.7 cells. Data are expressed as mean ± SD for (n=9) 
and analyzed by one-way ANOVA. Identical letters within the same panel are not significantly different at 
p ≤ 0.001 compared to LPS treatment group. Abbreviations TCD and IDG denotes 3β,7β,25-







In this study, a new cucurbitane-type triterpene aglycone and a known phytosterol, 
together with two previously identified compounds, were isolated from the fruit of M. 
charantia. These compounds showed variable α-amylase and α-glucosidase inhibitory 
activities, ranging from 56–79%. Our molecular docking studies for these enzymes 
revealed that all these compounds predominantly occupied the active site of the enzymes 
and formed H-bonds between the enzyme and hydroxyl groups in the cucurbitane 
skeleton. In the α-amylase molecular docking study, compounds 1–4 showed interactions 
with crucial amino acid residues including Glu233, Trp59 and showed binding energies 
between -8.76 and -11.98 kcal/mol with inhibition constants of 1.65–377 nM. Similarly, 
in the α-glucosidase molecular docking studies, compounds 1–3 showed interactions with 
crucial amino acid residue Arg442 and binding energies of -10.57 to -10.88 kcal/mol. 
Furthermore, the isolated compounds were screened for anti-inflammatory activities using 
RAW 264.7 macrophages. The results indicated that the compounds isolated from bitter 
melon have the potential to act as anti-inflammatory agents by lowering the expression of 
inflammation-related markers. Much more information is required to identify bitter melon 
as an antidiabetic agent positively, but the results of this study indicate that bitter melon, 







CHAPTER 4  
IN VITRO AND IN SILICO ANTIDIABETIC AND ANTI-INFLAMMATORY 




Bitter melon (Momordica charantia) is a tropical vegetable has been used to manage 
diabetes and related conditions. In the present study, ten compounds were isolated from 
acetone and methanol extracts of bitter melon. The chemical structures of compounds 
were unambiguously elucidated by 1D, 2D NMR, and high-resolution electrospray 
ionization mass spectrometry. All compounds exhibited significant inhibition of α-
amylase activity and moderate inhibition of α-glucosidase activities. Momordicoside G 
(5) showed the highest α-amylase inhibition of 70.46% and 2-hydroxy-5-O-β-D-
xylopyranosyl benzoic acid (7) showed the highest α-glucosidase inhibition of 56.37%. 
Furthermore, molecular docking studies of isolated compounds substantiated in vitro 
findings in which compounds 1–7 were able to bind to the active sites of both enzymes. 
Additionally, the isolated compounds significantly attenuated lipopolysaccharide (LPS)-
induced inflammation, downregulating the expression of pro-inflammatory markers NF-
κB, INOS, IL-6, IL-1β, TNF-α, and Cox-2 in murine macrophage RAW264.7 cells 
activated by LPS. Moreover, 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) was 
isolated for the first time, and it significantly suppressed the expression of Cox-2 and IL-




anti-diabetes drugs, our findings suggest that compounds purified from bitter melon may 
have potential to use as functional food ingredients for the prevention and treatment of 




Bitter melon (Momordica charantia L.,) is a popular vegetable that has good 
nutritional value and is typically used as a food in different parts of the world. 124 
Moreover, bitter melon is commonly used for the treatment of diabeties and related 
conditions by indegenous populations of tropical and subtropical areas commonly used by 
indigenous populations of tropical and subtropical areas such as East Africa, Asia, South 
America, and the Caribbean. 21, 38  Previous in vitro and in vivo pharmacological 
investigations on M. charantia have demonstrated that the extracts and bioactive 
compounds help in regulating glucose uptake, 74, 75 stimulate insulin secretion from 
pancreatic cells, 62, 76 protect pancreatic 𝛽-cells from inflammatory conditions, 77 display 
insulin mimetic activities and reduce lipid accumulation in adipocytes. 78  
Bitter melon has recently received much attention due to its cucurbitane-type 
triterpenoids contents and their various biological activities. At latest count, more than 
240 cucurbitane-type triterpenoids and their glycosides have been isolated and purified 
from various plant parts of bitter melons. 45, 125 These compounds exhibit several 
biological activities including anti-diabetic, 126, 127 antioxidant, 128 anti-inflammatory, 105 




known about the specific bioactive compounds responsible for these antidiabetics and the 
anti-inflammatory properties due to minute quantity of compounds available in bitter 
melons.  
Despite significant developments over the last several years in treating type 2 
diabetes, no curative agents responsible for reducing the risk of type 2 diabetes have been 
uncovered. The increase in diabetes rate has been primarily attributed to increased 
weight gain, leading to obesity. 133 Several synthetic drugs have been used to manage the 
disease including sulfonylureas, biguanides, thiazolidinediones, acarbose, and voglibose. 
95 Some of these drugs may prevent, delay or mask the occurrence of type 2 diabetes in 
case of a patient with impaired glucose tolerance. However, current therapeutic 
approaches have not appreciably altered the high incidence of diabetic complications. 134 
Several synthetic drugs are also associated with side effects such as hypoglycemia, weight 
gain, and other severe complications. These conditions demand the development of safe 
and biologically active natural antidiabetic drugs that have less adverse effects than 
existing synthetic medications. 
Acute inflammation is a necessary part of the body’s defense processes to 
eliminate injurious stimuli to initiate healing. In contrast, chronic inflammation (CI) has 
been correlated with various diseases and disorders. 135 Inflammation and its acute 
responses are well understood, whereas very little is known on the development and 
progression of chronic inflammation. During this process, an increase in macrophage cells 
plays an essential role in defense at the inflammatory sites. However, these macrophages 




Macrophages at the inflammatory site further stimulate chronic inflammation, activating 
the expression of genes encoding cycloxygenase-2 (COX-2), inflammatory cytokines 
(TNF-α and NF-κB). 137 Chronic inflammtion is a common feature in the natural course of 
diabetes, and the inflammatory mediators correlate with diabetic incidence and 
prevalence. Inflammatory responses contribute to type 2 diabetes incidence by triggering 
insulin resistance, and in turn, they are intensified in the presence of hyperglycemia and 
promote long-term diabetic complications. 138  
The present paper reports the extraction, purification and structure elucidation of 
10 compounds from the polar extracts of bitter melon. The purified compounds were 
evaluated for α-amylase and α-glucosidase inhibition assay for the first time and tested for 
molecular docking studies. Furthermore, purified compounds were evaluated for anti-
inflammatory properties using lipopolysaccharide (LPS)-activated RAW264.7 
macrophage cells.  This is the first report on isolation and identification of 2-hydroxy-5-
O-β-D-xylopyranosyl benzoic acid.  
 
4.3 Materials and methods 
 
4.3.1 General experimental procedures 
 
The purification of compounds was carried out on a flash chromatography system 
(Combiflash Rf, Teledyne ISCO, Lincoln, NE, USA). An Agilent 1200 Series HPLC 




µm) (Phenomenex, Torrence, CA), with a flow rate of 0.8 mL/min was used for the 
analysis of individual fractions. Optical rotations for compound 7 was taken on a  ATAGO 
SAC -i polarimeter in MeOH at 25 °C. UPLC-HRESIMS were recorded on a maXis 
impact mass spectrometer (Brucker Daltonics, Billerica, MA) coupled to a 1290 Agilent 
LC (Agilent, Santa Clara, CA) controlled by Bruker software (Bruker Compass 
DataAnalysis Version 4.2). The NMR spectra 1D (1H; 13C and DEPT 135) and 2D NMR 
spectra were recorded on a  JEOL spectrometer (USA, Inc., Peabody, MA) at 25°C, 
operating at 400 MHz (1H) and 100 MHz (13C) using standard JEOL pulse programs. 
Chemical shifts are given in δ (ppm) and were referenced to CD3OD (δH 3.31 and δC 
49.15), and coupling constants are reported in Hz.  
 
4.3.2 Plant material and extraction using Soxhlet apparatus 
 
The unripened fruits of M. charantia (120 kg) were purchased from a local 
marketplace (BCS Food Market, College Station, TX). Seeds were separated, and fruits 
were cut into small pieces. Fruits were air dried and powdered (40–60 mesh size) using a 
Vita-prep™ blender (Vita-Mix Corporation, Cleveland, OH). Total fruit powder (5.6 kg) 
was extracted with acetone and methanol using a Soxhlet like an apparatus at 60–70°C for 
32 h. Extracts were concentrated using rotary evaporator (Buchi, New Castle, DE), to 






4.3.3 Fractionation of acetone extract  
 
The acetone  crude extract (33.8 g) was chromatographed over silica gel (2.5 Kg 
silica-gel 60 Å 40-63 µm)  and was eluted with n-hexane, n-hexane/EtOAc (95:5, 90:10,  
85:15, 80:20, 60:40, 50:50, 40:60, 25:75 and 0:100 v/v) and similar step gradient with 
EtOAc/acetone, acetone/MeOH to afford 54 fractions of 250 mL each. On the basis of 
TLC analysis, fractions were pooled and concentrated under vacuum to afford eight 
subfractions (A1-A8).   The schematic procedure for fractionation of acetone crude extract 
of M. charantia is shown in Figure. A11. 
 
4.3.4 Purification of cucurbitane triterpenes by flash chromatography 
 
Subfraction A3 (7.24 g) was impregnated with 3g of silica gel and subjected to 
flash chromatography in a 240 g silica gel cartridge at 60 mL/min using a gradient program 
with n-hexane:EtOAc from 100–0% to 0-100 % and similar gradient was followed with 
EtOAc/acetone to afford 150 fractions of  1.5 l (150×15 mL each) and were pooled based 
on silica gel TLC profiles to give subfractions B1–B15. Fraction B8 (859 mg) was further 
subjected to cross column using reversed-phase C18 flash chromatography (RP-Cosmosil 
140 C18 column of 43 g) using H2O: MeOH (100–0%, 60 mL/min) linear gradient to 
afford 80 fractions, 1200 mL (80×15 mL each).  Fractions were analyzed using HPLC and 




(15:85) were pooled to yield compound 1 (12.3 mg), and similarly, fractions 71-77, RT 
14.9 min, H2O: MeOH (05:95) were pooled to yield compound 2 (14 mg). 
Similarly, subfraction A5 (7.48 g) was impregnated with 2.5 g of silica gel and 
subjected to flash chromatography in a 240 g silica gel cartridge, at 60 mL/min using a 
gradient with n-hexane/EtOAc from 100–0% to 0-100%. In total, 180 fractions, 2.7 l 
(180×15 mL each) were collected and pooled based on silica gel TLC profiles to give 
subfractions C1–C10. Fraction C7 was subjected to cross column using C18 reversed-
phase flash chromatography using H2O: MeOH (100–0% to 0-100%, 35 mL/min) to afford 
120 fractions, 1.8 l (120×15 mL each) which were analyzed using HPLC.  Fractions (104-
107) yielded compound 3 (13 mg).    
Similarly, subfraction A8 (11.32 g)  was subjected to 320 g silica gel flash 
chromatography using n-hexane/EtOAc gradient elution from 100-0% to 0-100% at 200 
mL/min followed with EtOAc/acetone (100-0% to 0-100%) to afford 240 fractions, 3.6 l 
(240x15 mL each). Based on silica TLC profile fractions were pooled into 13 subfractions 
(D1-D13). Fractions D9 (1.33 g) from this chromatography were subjected to repeated 
silica gel flash chromatography and C18 reversed-phase flash chromatography to afford 
compound 4 (22.7 mg) and compound 5 (46 mg). Fraction D11(921.3 mg) was further 
subjected to repeated flash chromatography over C18 reversed-phase silica gel flash 







4.3.5 Fractionation methanol extract 
 
 MeOH extract of (47 g) was loaded to the activated dowex-50 (H+) column. The 
eluate from the dowex column was connected to the SP-70 column. The dowex column 
was washed with excess water, and the eluate was then absorbed on the SP-70 column. 
Later SP-70 column was eluted with linear gradient mobile phases consisting of 
acetonitrile (ACN) in water. The eluants obtained using 100 % water were collected 
analyzed using HPLC and concentrated under vacuum to afford subfractions A1-A3. 
Fraction A1 of (2.3 g)  was subjected to cross column using C18 reversed-phase silica gel 
flash chromatography (RP-Cosmosil 140 C18 column of 43 g) using H2O: MeOH (100–
0%, 35 mL/min flow rate) to afford compound 7 (33 mg). Furthermore, fraction A3 of 
(5.7 g) was subjected to cross column using reversed-phase C18 flash chromatography 
(RP-Cosmosil 140 C18 column of 43 g) using H2O: MeOH (100–0%, 60 mL/min) to 
isolate and identify compounds 8, 9 and 10. 
 
4.3.6 Determination of absolute configuration of the sugar 
 
The compound 7 (1 mg) was hydrolyzed by heating in 1M HCl (0.1 mL) and 
neutralized with Amberlite IRA400. After sample mixture was dried in vacuo, the residue 
was dissolved in pyridine (0.1 mL) containing L-cysteine methyl ester hydrochloride (0.5 
mg) and heated at 60 °C for 1 h. A 0.1 mL solution of o-torylisothiocyanate (0.5 mg) in 




mixture was analyzed by reversed-phase HPLC. Xylose was identified by comparison of 
the HPLC retention times of thiocarbamoyl thiazolidine derivatives prepared from sugar 
standards.  
 
4.3.7 -amylase inhibition assay 
 
To understand the hyperglycemic activities of isolated compounds -amylase was 
carried out using a published protocol with minor modifications. 139 Purified compounds 
10 and 20 µL (equivalent to 0.43 and 0.86 mM) was used in the assay and results were 
compared with acarbose (10 and 20 µl equivalent to 0.067 and 0.13 mM). All experiments 
were conducted in triplicates with three biological replications.  
 
4.3.8 -glucosidase inhibition assay 
 
Similarly, α-glucosidase inhibitory activity was evaluated using a published 
protocol with slight modifications 109. All experiments were conducted in triplicates with 
three biological replications. Compounds 10 and 20 µL (equivalent to 0.67 and 1.13 mM) 
were used and results were compared with positive control. 
 
4.3.9 In silico molecular docking studies  
 




α-amylase and α-glucosidase, a molecular modeling study was performed for both.    
 
4.3.9.1 Protein structure preparation 
 
The X-ray crystal structures of Porcine Pancreatic -amylase complexed with 
acarbose (PDB ID: 1OSE) and for -glucosidase, the crystal structure (PDB ID:3A4A) of 
isomaltase from S. cerevisiae proteins were downloaded from the RCSB protein data bank 
( http://www.rcsb.org/pdb) in PDB format. Later, both proteins were prepared by 
removing all water molecules, and a CHARMm force field was applied using the 
Receptor-Ligand interactions tool in DS (Biovia Discover4y studio 4.5 (DS 4.5, Dassault 
Systems BIOVIA, Discovery Studio Modeling Environment, Release 4.5, San Diego. 
2015). Further, active residues of the crystal structure of 1OSE and 3A4A were identified 
using the Computer Atlas of Topography of Proteins (CASTp), a program for identifying 
and characterizing active protein sites, binding sites, and functional residues located on 
the protein surface.  
 
4.3.9.2 Preparation of ligands 
 
Two-dimensional structures of purified compounds were drawn using ChemDraw 
tool (PerkinElmer Informatics, 2016) and saved as a molecular format file (MDL MOL 
format). The “Prepare ligand” protocol of DS 4.5 was used to prepare the ligands which 




ions and ionization of the ligand’s functional groups, 2D-3D conversion, verifying and 
optimizing the structures, and other tasks established by user-defined parameters. All the 
ligands were typed with the CHARMM36 force field using DS4.5 and saved as PDB 
format. 
 
4.3.9.3 Molecular docking  
 
The seven ligands were docked with -amylase and -glucosidase using the 
Lamarckian genetic algorithm (LGA) provided by the AutoDock 4.2 Program (ADT, 
version: 1.5.6). Polar hydrogens were added to the receptor, Kollman charges were 
assigned, and solvation parameters were added with the “Addsol” option in AutoDock. 
For the inhibitors, charges of the Gasteiger type were assigned. The internal degree of 
freedom and torsion were defined using the “Ligand Torsions” menu option of 
AutoDock. The grid maps representing the protein were calculated using the “AutoGrid” 
option. The protein was centered on the geometric center before docking, and the 
dimensions of the cubic grid box were set to 126 Å of x, y, and z with a spacing of 0.375 
Å for both proteins. Blind Docking was carried over the whole receptors (i.e., 1OSE and 
3A4A) using Genetic Algorithm.  The best ligand-receptor structure from the docked 
structures was chosen based on the lowest energy and minimal solvent accessibility of 
the ligand. The 2D visualization of ligand interactions with the protein domain was 




Graphics System, San Carlos, CA, USA) was used to visualize the 3D interactions 
between ligands and receptors better. 
 
4.3.10 Cell culture 
 
The RAW 264.7 mouse monocyte-macrophage cell line is cultured in RPMI 1640 
medium (VWR International (Radnor, PA)) supplemented with 10% (v/v) fetal bovine 
serum and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). Cells were 
maintained in a humified atmosphere with 5% CO2 at 37 °C. 
 
4.3.10.1 Quantitative real-time polymerase chain reaction (qRT-PCR)  
 
RAW 264.7 cells were plated at 5.0×105 cells/well into 6-well plates and incubated 
at 37°C and 5% CO2 for 24 h. Following incubation, the cells were treated with 25 μM of 
purified compounds (1–7) dissolved in DMSO for 1 h. After 1 h, LPS (1 µg/mL) was 
added to specified wells, and the cells were incubated for an additional 18 h. LPS was 
freshly prepared as stock solution in saline at 1µg/mL, and freshly diluted in complete 
media and added to the specified wells. Following the incubation period, media was 
aspirated, cells washed with PBS, and detached and collected. Total RNA was extracted 
using the Aurum Total RNA Mini Kit (Bio-Rad). RNA concentrations were determined 
using a Nanodrop Spectrophotometer (Thermo Scientific NanoDrop Products). Purified 




manufacturer’s manual (iScript cDNA Synthesis Kit, Bio-Rad). Real-time PCR was 
performed on a Bio-Rad using the SYBR Green PCR Master Mix, according to the 
protocol provided by the manufacturer and relative expression was compared and 
normalized to the expression of GAPDH in the same sample. Primers sequences are 
available upon request. 
 
 4.3.11 Statistical analysis 
 
Statistical analysis was performed using JMP Pro14 (SAS, NC, U.S.A.) statistical 
software. Results were analyzed for normality with Shapiro–Wilk test and the variance 
with the Brown-Forsythe test. Based on the results of the Brown-Forsythe test one-way 
analysis of variance (ANOVA) was run. To evaluate significance differences between 
means Tukey’s HSD test was run. A p-value of p< 0.001 was accepted as statistically 
significant, results are expressed as mean ± SD. 
 
4.4 Results and discussion 
 
4.4.1 Isolation and Structural elucidation of compounds 
 
Ten compounds were isolated from methanol and acetone extracts of bitter melon. 
A schematic diagram of the isolation of compounds 1-10 is shown in Figure A16. The 




chromatography. HPLC was used analyze fractions, and fractions containing same peaks 
containing fractions were pooled, lyophilized further, and subjected to flash 
chromatography to obtain six mono glycoside cucurbitane-type triterpenes. Compounds 
1-6. Compounds 1-6 were characterized by 1D and 2D NMR and high-resolution mass 
spectroscopic data. The complete assigned 1H and 13C NMR spectra are presented in 
Figure A17-A28 and the respective spectral data has been depicted in Tables 5 and 6. The 
high-resolution mass spectra of the compounds 1-10 were presented in Figure A29. On 
the basis of spectral data, compounds 1-6 were identified as momordicoside I, F1, K, F2, 
G and karaviloside XI, respectively. The chemical shifts were compared with reported 
values. 140, 141  The MeOH extract was subjected to flash chromatography to obtain 
compounds 7-10. Compound 7 was isolated as an amorphous white powder with optical 
rotation [α]25D +46.9 (c 0.1, MeOH). High-resolution electrospray ionization mass 
spectrometry (HR-ESIMS) and HR-ESIMS/MS data of compound 7 in negative ion mode 
showed a molecular ion at m/z 285.0602 [M−H]− (calculated m/z 285.0611 [M−H]−), 
suggesting a molecular formula C12H14O8. The loss of one pentose was observed through 
the fragment at m/z 152.0105 ([M-H]-H2O-132 Da)−  with a further loss of -COOH 
evidenced for the fragment at m/z 108.0210 ([M-H]-44 Da)−. Acid hydrolysis of 7 
furnished D-xylose, which was identified by comparison of the HPLC retention times of 
thiocarbamoyl thiazolidine derivatives prepared from sugar standards as previously 
described. 142 1H NMR data showed two main groups of signals, one related to an aromatic 
region and the second one due to sugar region. The aromatic protons exhibited a typical 




(J=3.0 Hz). An anomeric proton was also observed at δH 4.73 ppm with a beta linkage due 
to the large coupling constant. DQFCOSY showed two aromatic spin systems through 
correlation among the three aromatic protons and also among the sugar protons. The 
HMQC spectra was used to assign direct C-H correlations (Figure 8A), indicating δC 
114.1; 151.1 and 158.9 ppm as quaternary carbons and 173.3 ppm as a carbonyl group 
from a carboxylic acid, according to HR-ESI-MS/MS. Cross-peak 3J HMBC correlations 
were used to assign the aromatic ring, 7.54 ppm showed correlations with 158.9 ppm and 
the carbonyl group at 173.3 ppm, indicating that the carboxylic acid group is ortho to H-
6. In the same way, 7.24 ppm (H-4) showed 3J HMBC correlations with 119.1 (C-6) and 
158.9 ppm (C-2), and 6.86 showed 3J HMBC correlation with 114.1 ppm (C-1) and 151 
ppm (C-5) (Figure 8B). The xylose was found to be attached at δC 151 ppm due to the 
HMBC cross-peak with the anomeric proton (4.73 ppm). DQFCOSY showed the 
correlation between the anomeric proton and 3.40 ppm (74.8 ppm) and 3.92 ppm (H-5) 
with 3.59 ppm (H-4). Additionally, 3J HMBC correlation between 77.8 ppm with 3.92 
ppm corroborated the position 3 of the sugar. Thus, compound 7 was named as 2-hydroxy-
5-O-β-D-xylopyranosyl benzoic acid, shown in Figure 9. HPLC-UV, HRESIMS, fully 
assigned 1D, 2D NMR data for compound 7 were shown in Figure A30-A34. 1H and 13C 
chemical shifts are presented in Table 5 and 6 respectively. This is the first report on the 




Table 5 1H NMR data for compounds (1-7) from acetone extract of Momordica charantia, (MeOD, 400 
MHz, δ in ppm) 
 
  
1 2 3 4 5 6 7 
1 1.39;1.39 m 1.40;1.40 m 1.63 m;1.63 m 1.44; 1.13 m 0.92; 1.42 m 1.45; 1.45 - 
2 0.93;1.01 m 1.76;2.12 m 1.69m; 1.69m 2.16; 1.79 m 2.12; 2.16 m 2.75; 1.78 - 
3 3.37 s 3.39 br s 3.55 br s 3.40 m br s 3.39 br s 3.41 br s 6.86 d 
 (J=9.0 Hz) 
4       7.24 dd 
(J=9.0; 3.0 
Hz) 
6 6.02 dd 
(J=9.9;1.9 Hz) 
6.09 dd  
(J=9.8; 1.8 Hz 
5.97 d (J=4.4 
Hz) 




7 5.55 dd 
(J=9.8;3.8 Hz) 
5.63 dd  
(J=9.9; 3.8 Hz) 
4.18 d (J=5.6 
Hz) 
6.10 d (J=10 
Hz, 1H) 










2.26 m 2.57 dd  
(J=4.4 Hz,4 
Hz) 
2.29 m 2.26 m 2.31 m - 
11 1.49; 1.69 m 1.72; 1.77 m 1.45 m; 1.45 
m 
1.74; 1.74 m 1.71; 1.75 m 1.75; 1.53 m - 
12 1.56; 1.72 m 1.62;1.74 m 1.26 m; 1.26 
m 
1.64; 1.77 m 1.57; 1.72 m 1.69; 1.69 m - 
14 
      
- 
15 1.32; 1.32 m 1.35; 1.35 m 1.40 m; 1.40 
m 
1.36; 1.36 1.32; 1.34 m 1.37; 1.37 m - 
16 0.86; 1.23 m 1.36;1.36 m 1.39 m; 1.39 
m 
1.30; 1.30 1.27; 1.27 m 2.04; 1.51 m - 
17 1.51 m 1.53 m 2.10 m 1.55 m  1.49 m 1.49 m - 
18 0.84 m 0.93 m 0.94 s 0.93 s 0.91 s 0.96 - 
19 3.14; 3.46 m 3.52 d (J=8.0 
Hz); 3.65 m 
9.85 s 3.53; 3.66 m 3.49; 3.63 m 3.67; 3.53 d 
(J=7.9 Hz) 
- 
20 1.50 m 1.59 m 1.58 m 1.54 m 1.59 m 1.75 m  
21 0.86 s 0.93 m 0.96 d (J=4 
Hz) 
0.95 m 0.92 m 0.99 (J=6.3 
Hz) 
- 
22 2.13; 2.09 m 1.80;1.88 m 2.26 m; 2.20 
m 
1.82; 2.21 m 1.86; 2.19 m 1.94; 0.95 m - 
23 5.50 m 5.57 dd 
(J=8.7;5.8 Hz) 
5.59 m 5.59 m 5.58 dd  





24 5.50 m 5.37 d (J=15.8 
Hz) 




5.46 d (J= 16 
Hz, 1H) 
3.05 (1H, d -
like) 
- 
26 1.18 s 0.93 m 1.25 s 1.27 s 1.24 s 1.27 s - 
27 1.18 s 1.24 s 1.25 s 1.27 s 1.23 s 0.95 s - 
28 0.84 m 1.12 s 1.25 s 1.28 s 1.11 s 0.95 s - 
29 1.17 s 0.93 m 1.09 s 0.95 s 0.92 s 1.24 s - 







-    
7-O-β-Glc 3-O-β-All 3-O-β-All 3-O-β-All - 
1' 4.2 d (J= 8.0 
Hz) 
4.23 d (J=8.0 
Hz) 
4.24 d (J=8 
Hz) 
4.63 d (J=8 
Hz, 1H) 





4.73 d (J= 
8.0Hz) 
2' 3.19 m 3.20 m 3.14 m 3.34 3.32 4.08 3.40 m 
3' 3.20 m 3.22 m 3.24 m 4.07 4.04 3.35 3.40 m 
4' 3.29 m 3.32 m 3.25 m 3.46 3.47 3.48 3.59 m 
5' 3.32 m 3.35 m 3.35 m 3.67 3.64 3.68 3.92; 3.31 
6' 3.77; 3.60 m 3.86; 3.64 dd 
(J=11.6;2.4 Hz) 
3.90 dd; 3.64 
m (J=12 Hz, 
J=2.1 Hz) 





Table 6 13C NMR data for compounds (1-7) from acetone extract of Momordica charantia (MeOD, 100 






























Position 1  2  3  4  5  6  7 
1 19.6 19.6 22.5 19.6 19.6 19.6 114.1 
2 28.3 28.3 30.3 28.3 28.2 28.3 158.9 
3 87.2 87.1 77.2 87.2 87.2 87.2 119.0 
4 39.9 39.9 42.5 39.8 39.8 39.8 127.1 
5 87.9 87.9 148.1 87.9 87.9 87.9 151.1 
6 134.0 134.0 123.5 131.6 131.6 134.1 119.1 
7 131.7 131.6 73.6 134.1 134.1 131.7 - 
8 53.5 53.4 51.4 53.5 53.5 53.5 - 
9 46.6 46.6 51.4 50.0 50.0 46.1 - 
10 41.1 41.1 37.5 41.1 41.1 41.1 - 
11 24.8 24.7 23.3 24.8 24.8 24.8 - 
12 32.1 32.1 30.0 32.1 32.1 32.4 - 
13 46.1 46.1 47.1 46.1 46.1 46.7 - 
14 50.0 50.0 48.5 46.6 46.6 50.0 - 
15 34.5 34.5 35.9 34.5 34.5 34.4 - 
16 29.2 29.2 28.5 30.9 30.9 29.3 - 
17 51.4 51.4 46.8 51.4 51.4 52.7 - 
18 15.6 15.6 15.6 15.6 15.6 15.6 - 
19 80.9 80.9 210.3 80.9 80.9 80.9 - 
20 37.7 37.5 37.6 37.7 37.9 33.5 - 
21 19.3 19.4 19.4 19.3 19.3 19.2 - 
22 40.4 40.6 40.6 40.5 40.6 43.5 - 
23 126.0 130.1 130.2 126 130.2 68.6 - 
24 141.0 137.8 137.8 141 137.8 80.3 - 
25 71.3 76.6 76.6 71.3 76.7 74.7 - 
26 30.3 26.7 26.6 30.3 26.3 27.5 - 
27 30.2 26.4 26.4 30.2 20.6 26.4 - 
28 20.8 20.5 26.2 29.2 26.3 20.8 - 
29 26.4 26.2 28.0 26.4 26.4 26.3 - 

















1′ 107.8 107.8 102.3 105.1 105.1 105.1 104.3 
2ʹ 75.4 75.4 75.1 72.6 72.6 73.0 74.8 
3ʹ 77.9 77.9 78.3 73.0 73.0 72.6 77.8 
4ʹ 71.9 71.9 71.8 69.1 69.2 69.2 71.1 
5ʹ 77.7 77.7 78.2 75.4 75.4 75.4 67.0 
6ʹ 63.0 63.0 63.0 63.4 63.4 63.4 - 




Compounds 8-10 were isolated from methanol extract and identified using HR-
ESIMS and NMR; results were compared with published literature. 143, 144 Based on these 
data, compounds 8-10 were identified as benzoic acid (8), quercetin 7-O-β-
glucopyranoside (9) and phenylalanine (10) respectively. 
 
4.4.2 In vitro inhibition activity of -amylase and -glucosidase 
 
Anti-diabetic compounds often inhibit carbohydrate-degrading enzymes; therefore 
we tested compounds 1-7 for inhibition of -amylase and -glucosidase activity, 
compared with the known inhibitor acarbose. In the -amylase inhibition assay, purified 
compounds 1-7   exhibited significant inhibition of -amylase at 0.43 mM and 0.87 mM, 
ranging between 63-70 % but lower than acarbose (88% inhibition at 0.13 mM). However, 
higher inhibition was observed at 0.87 mM. Among momordicoside G (5) showed highest 
α-amylase inhibitory activity (70.5%), followed by momordicoside K (3) (69.0%), 
karaviloside XI (6) (66.4%), momordicoside I (1) (64.2%), momordicoside F2 (4) 63.7%), 
momordicoside F1 (2) (63.5%), and 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) 
(60.7%) (Figure 10A).  
Similarly, the purified compounds 1–7 showed moderate inhibition of α-
glucosidase at 0.67 and 1.33 mM. Among the tested compounds, 2-hydroxy-5-O-β-D-
xylopyranosyl benzoic acid (7) showed maximum (56.4%) inhibition followed by 
karaviloside XI (6) (49.4%), momordicoside G (5) (48.5%), momordicoside K (3) 





Figure 8 Complete assignments of (A). HMQC spectra, traces of one-dimensional 1H spectrum and 13C DEPT-135 spectrum (CH negative C and CH2 
negative) are also shown, (B). HMBC spectra and 1H-NMR on X-axis and APT is on Y-axis of the spectrum of 2-hydroxy-5-O-β-D-xylopyranosyl 










momordicoside I (1) (35.1%) at 1.33 mM. In both enzymatic assays, momordicoside G 
(5) and karaviloside XI (6) showed maximum inhibition. (Figure 10B). In both enzymatic 
assays, momordicoside G (5) and karaviloside XI (6) showed relative maximum 
inhibition.  
 Bitter melon has gained much attention for the treatment of diabetes mellitus. 
The inhibition of the carbohydrate digesting enzymes helps in reducing post-prandial 
blood glucose by delaying starch hydrolysis. The beneficial effects of the bitter melon 
extracts and the mechanism with which it treats diabetes mellitus have been extensively 
studied. 145, 146 A previous study reported momordicoside G, I, F1 and F2 as weak α-
glucosidase inhibitors. In the same study, more polar compounds, momordicoside A and 
M, which have two sugar moieties at the C-3 position and multiple hydroxyl groups, 
showed stronger α-glucosidase inhibitory activity (21.71% and 18.63% inhibition at the 
concentration of 50 µM). 126 
Karaviloside XI has a sugar moiety at C-3 and three hydroxyl groups at position 
C-24, 25 and 26 showed strong α-glucosidase inhibitory activity compared to other 
cucurbitane mono glycosides. Another study on α-glucosidase inhibitory activity 
demonstrated that compounds bearing a β-D-allopyranosyl group at C-3 exhibited higher 
inhibitory activity than compounds bearing a β-D-glucopyranosyl group at C-3. 
Interestingly, we observed a similar trend in our study where momordicoside G (5) and 
karaviloside XI (6) were the most active compounds against both the enzymes (Figure 
10). The higher inhibitory activity of momordicoside G and karaviloside XI compared to 




notable effect on the inhibitory activity against both the enzymes. Also, momordicoside 
F1, K, I and G showed weaker α-amylase activity compared to acarbose at 100 µM. 147 
However, in the present study, all compounds 1-7 showed significant effects and exhibited 
the same potency of α-amylase inhibition at 0.87 mM.  
 
4.4.3 Molecular docking study 
 
4.4.3.1 Virtual screening of α-amylase inhibitors 
 
Molecular docking uses chemometrics methods to simulate, identify and predict 
the structure of receptor-ligand complex according to the lock and key principle of .148 
Therefore, we used in silico by molecular docking to examine the inhibitory activity of 
compounds 1–7 towards α-amylase and -glucosidase.  
Molecular docking for -amylase was conducted with the crystal structure of 
porcine pancreatic α-amylase (PDB ID:1OSE), downloaded from the protein data bank. 
The refined  -amylase structure is well characterized and has a network of water 
molecules occupying the cleft of the active sites and hydrogen-bonding with polar side 
chains of Asp300, Glu233, and Aspl97, with the chloride ligand Asn298, and with the 
main chain through Ala307 N and Trp59. Also, the binding cleft is characterized by 
aromatic residues such as Trp58, Trp59, Tyr62, His101, Pro163, Ile235, Tyr258, His305, 




Binding energies of compounds 1-7 ranged from -8.23 to -11.83 kcal/mol. The 
likeliest docked poses of compounds with best binding affinity for α-amylase at the 
catalytic site were selected and are shown in Figure 11(A-G). Momordicoside K (3) 
showed the lowest binding energy (-11.83 kcal/mol), followed by momordicoside G (5) (-
10.76 kcal/mol), karaviloside XI (6) (-10.48 kcal/mol), momordicoside I (1) (-10.27 
kcal/mol), momordicoside F1 (2) (-10.11 kcal/mol), momordicoside F2 (4 ), and 2-
hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) (-8.23 kcal/mol). Lower binding energy 
corresponds to easier binding of a ligand to the protein.  Hence momordicoside K is most 
favorable to bind with the α-amylase. Furthermore, a detailed analysis of the docked poses 
regarding ligand-protein binding energy, the number of  H-bonds, and the inhibition 
constant are shown in Table 3. In Figure 11 (A-G) the ligand in the active site of α-
amylase is displayed as a stick model and colored green. The carbon, hydrogen and oxygen 
atoms on an amino acid residue are displayed as white, blue and red, respectively. The 
hydrogen bonds are shown in yellow dashed lines to judge interaction between receptor 
and ligand.  
As shown in Figure 11(A-G) and Figure A35 (A-G), compound 1-7 were 
surrounded by crucial amino acid residues including Asp300, Glu233, Asp197, Gly308, 
Gly306, Gly238, Trp58, His305, Trp59, Val163, Leu162, Lys200, His201, Ile235, and 
Glu240 in domain A of -amylase. The docking result Figure 11(A-G) showed that the 
binding site on α-amylase for momordicoside I, F1 K, F2, G, karaviloside XI, and 2-
hydroxy-5-O-β-D-xylopyranosyl benzoic acid were same as the binding site of acarbose 




diabetes via inhibiting α-amylase, was found to be an anchor at enzymatic pocket (domain 
A) of α-amylase and bound to residues including Asp197, Glu233, and Asp300, resulting 
in potent inhibition of -amylase 150. These residues are believed to play crucial roles in 
the catalytic mechanism of -amylase. Moreover, it was observed that the binding site for 
compounds 1-7 was inside the binding site pocket of α-amylase by forming various 
hydrogen bonds. Momodicoside I (1) was surrounded by Glu233, Arg195, Gly306, 
Gly308, Asp300, and His305 respectively. Similarly, the refined docking of 
momordicoside F1 (2) with -amylase (Figure 11B and Figure A35B) generated the best 
pose with minimum inhibition constant of 39.1 nM. Momordicoside F1 was surrounded 
by Asp197, Asp300, Gly308, and His307 respectively. We also observed strong Van der 





Figure 9 Chemical structures of isolated compounds (1–10) from the acetone extract of Momordica  
charantia
1. R1=Glc R2=OH    (momordicoside I)
2. R1=Glc R2=OMe (momordicoside F1)
4.    R1=All         R2=OH     (momordicoside F2)
5.    R1=All         R2=OMe (momordicoside G)
3.  momordicoside K
6.  karaviloside XI 7.  2-hydroxy-5-O-β-D-xylopyranosyl
benzoic acid 







Figure 10 Effect of purified compounds (1-7) on the inhibition of (A). α-amylase (B). α-glucosidase. 
Acarbose was used as a positive control, and all the experiments were conducted in (n=3), biological 
replications), (n=3) test replications and analyzed by one-way ANOVA. The results are represented as 
means ± SD and analyzed by one-way ANOVA. Identical letters at each concentration are not 
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Moreover, its docking score was -10.11 kcal/mol, having a notable in vitro 
inhibition activity of α-amylase (63.5 %). On the other hand, momordicoside K (3) showed 
a potential inhibition activity of amylase (68.98%), and its docking score on this enzyme 
is the first among the other six scores (-11.83 kcal/mol). It was entirely wrapped in the 
active site of α-amylase by surrounding Asp197, Glu233, His201, Gly306, His101, 
Arg195, Tyr151, and Gly104 and His305. Momordicoside F2 (4) formed four hydrogen 
bonding with the α-amylase enzyme and had the binding energy of -9.58 kcal/mol which 
was the second least among the other six compounds. MomordicosideF2 (4) was 
surrounded by Asp300, Gly238, Gly306 respectively (Figure 11D and Figure A35D).  
Moreover, momordicoside F2 (4) showed comparable inhibition activity of 63.65% with 
compound 2.  Momordicoside G (5) with the binding energy of -10.76 kcal/mol occupied 
the active region of -amylase by making two hydrogen bonds between Asp300 and 
Asp197 and C-6', C-2' respectively.  (Figure 11E and Figure A35E). These hydrogen 
bonds overtly strengthened the interaction between momordicoside G and the enzyme 
catalytic site. Also, momordicoside G showed an excellent % α-amylase inhibition activity 
(70.46%) which was the highest among the other six compounds.  Similarly, karaviloside 
XI (6) was bound to the active site of -amylase with a binding energy of -10.48 kcal/mol. 
Karaviloside XI (6) was surrounded by Asp197, Asp300, Glu240 respectively (Figure 
11F and Figure A29F). These strong hydrogen bonds with the enzyme catalytic site were 
responsible for inhibiting the activity of α-amylase. Figure 11G and Figure A35G shows 
the binding mode of 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) in the active site 




active site of an enzyme by interacting with key amino acid residues Glu233, Ile235, 
Asp197, Arg195, His299, Tyr62, and Asp300. Based on the previous investigations, the 
present molecular docking, and in vitro assay study results, we concluded that the robust 
in vitro α-amylase inhibitory activity of compounds 1-7 might be due to binding to the 
side chain of Glu233, or Asp 197, and Asp 300 of α-amylase. In docking studies between 
flavonoids and human pancreatic α-amylase Asp197, Glu233, and His305 were reported 
to be the essential amino acid residues in forming hydrogen bonds and inhibition of α-
amylase. 151 In the present study, we noticed that hydroxyl groups on sugar moiety of 
compounds 1-7 are favorable for the ligand to interact with the amino acid residues of the 
binding pocket, mostly with Glu233, Asp197, and Asp300 and enhancing the activity of 
particular ligands. 
Among seven compounds, karaviloside XI formed nine hydrogen bonds with the 
enzyme and whose binding energy was second highest among the seven compounds 
(Table 7). This could be the due to the presence of multiple hydroxyl groups on the side 
chain and a sugar moiety. A 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid formed eight 
hydrogen bonds with the enzyme. However, we observed lower binding energy of -8.23 
kcal/mol. Similarly, momordicoside I and momordicoside G formed seven hydrogen 
bonds followed momordicoside K, momordicoside F1, momordicoside F2 which formed 
six, five and four hydrogen bonds with the enzyme respectively. Furthermore, we also 
observed the altered docking pose for momordicoside G, and Karaviloside XI compared 
to other compounds. Also, to support this, momordicoside G and Karaviloside XI showed 




different sugar moieties attached to the compounds and enzyme active pocket play an 







Table 7 Binding free energy of the ligand-receptor complex; the number of hydrogen bonds between compounds and the active site of the enzymes; of 
purified compound (1–7) with porcine pancreatic α-amylase (PDB ID: 1OSE) and α-glucosidase (PDB ID: 3A4A) 











Momordicoside I -10.27 7 His305, Asp300, Arg195, Glu233, Gly306, 
Gly308, Ala307, Ile235, Tyr151, His201, 
Ala198, Lys200, Leu162 
His305 (2.1) Asp300 (2.2 and 1.9), 
Glu233 (2.3), Arg195 (2.2), Gly306 




-10.11 5 His305, Asp300, Asp197, Gly308, Ala307, 
Tyr151, Lys200, Ile235, His201, Ala198, 
Leu162 
His 305 (2.1), Asp 300 (1.9 and 2.2), 




-11.83 6 Asp197, Glu233, His201, Ile235, Asp300, 
Leu165, Trp59, Val163, Leu162, His305, 
Gly306, Tyr151 
Asp 197 (1.9 and 2.7), Glu 233 (2.1), 





-9.58 4 Val163, Gly306, Asp300, Ala307, Ile235, 
Gly238, Lys200, Tyr151, Leu162, His201, 
Gly 306 (2.6), Asp 300 (2.0 and 2.5), 




-10.76 7 Ala107, Val51, Ile49, Trp59, TRp58, 
Asp197, Glu233, Gly306, Asp300, Ile235, 
Leu165, Val163 
Asp 197 (1.9, 2.0, and 2.3), Asp 300 
(2.0, 2.8, 3.1 and 3.2) 
12.9 
Karaviloside XI -10.48 9 Glu240, Tyr151, Ile235, Val163, Leu162, 
Asp197, Asp300, Leu237, Ala307 
Asp300 (2.0, 2.0 and 2.1), Glu240 






-8.23 8 Ser199, Val234, His201, Glu233, His101, 
Tyr62, Asp197, Arg195, His299, Ala198, 
Asp300 
Glu233 (1.9,2.1 and 2.3), Ile235(2.8), 







Momordicoside I -10.4 5 His280, Ser157, Tyr158, Phe178, Arg442, 
Asp69, Phe303, Arg315, Pro312 
Arg442 (2.0), Asp69 (1.8), Ser157 




-12.08 5 Ser240, Leu313, Phe303, Asp352, Glu237, 
Arg315, Tyr158, Phe314, Lys156,  
Ser240 (2.5), Leu313 (2.0 and 1.9), 




-10.69 6 His280, Arg315, Tyr158, Arg442, Asp352, 
Phe178, Phe159, Ser240, Leu313, Lys156, 
Ser157 
Arg442(3.5), Asp352 (2.6), Glu277 
(1.9), Ser240 (2.3), Leu313 (2.0), 




-11.43 5 Pro243, Pro312, Tyr158, Phe303, Glu277, 
Asp352, Arg315, Phe314, Leu313, Lys156, 
Pro243 
Pro312 (3.2), Glu277 (2.0), Asp352 




-9.9 5 Asn302, Ala281, His280, Ser157, Asn415, 
Tyr158, Pro312,  
Asn302 (2.3), Ala281 (2.0), Gly160 
(2.5), Ser157 (3.2 and 1.9) 
55.65 
Karaviloside XI -12.19 5 Asp315, Glu277, Asp352, Phe303, Tyr158, 
Arg315, His305, Leu313, Phe159 
Glu277 (2.0 and 2.0), Asp215 (1.9), 





-7.97 5 Ser241, Asp242, Tyr158, Pro312, Leu313, 
Val232, Asp233, Lys156, Ser240, Gln239, 
Ser157,  
Asp242 (3.9,3.6), Ser241 (2.9), 






Figure 11 The 3D ligand-protein interactions for (A). momordicoside I, (B) momordicoside F1, (C). momordicoside K (D). momordicoside F2 (E). 
momordicoside G, (F). karaviloside XI and (G). 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid in the binding pocket of -amylase respectively. The 




4.4.3.2 Virtual screening of isomaltase inhibitors 
 
The binding energy and the inhibition constants for α-glucosidase docking study 
are shown in Table 3. The 3D and 2D interactions found for the best poses are depicted in 
Figure 12A-12G and Figure A36A-A36G, respectively. To date, the crystal structure of 
α-glucosidase from S. cerevisiae (the enzyme used for the biological assay) has not been 
resolved. Therefore, the compounds were docked to the isomaltase crystal structure (PDB 
ID:3A4A) downloaded from the Protein Data Bank. 152  From the docking study, it was 
observed that all the compounds were well accommodated inside the active site of 
isomaltase.  
Binding energies of compounds (1-7) are ranging from -7.97 to -12.19 kcal/mol. 
The likeliest docked poses of compounds (1-7) with best binding affinity for isomaltase at 
the catalytic site were selected and are shown in Figure 12A-12G. Karaviloside XI (6) 
exhibited the lowest binding energy (-12.19 kcal/mol), followed by momordicoside F1 (1) 
(-12.08 kcal/mol), momordicoside F2 (4) (-11.43 kcal/mol), momordicoside K (3) (-10.69 
kcal/mol), momordicoside I (1) (-10.4 kcal/mol), momordicoside G (5) (-9.9 kcal/mol), 
and 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) (-7.97 kcal/mol).  
As shown in Figure 12(A-G) and Figure A36(A-G), compound 1-7 were 
surrounded by crucial amino acid residues including Ser157, Glu277, Glu411, Asp307, 
Gly353, Arg442, Asp69, His351, Asp352, Arg213, and Tyr347 of -glucosidase. 
Furthermore, a detailed analysis of the docked poses regarding ligand-protein binding 




In the isomaltase molecular docking study, momordicoside I (1) (Figure 12A and 
Figure A36A) was buried inside the active pocket site of isomaltase by surrounding with 
residues Ser157, Arg442, Asp69, Arg315, Phe303, His280, Tyr158, Arg442, and Phe178. 
Figure 12B and Figure A36B showed the binding mode of momordicoside F1 (2) in the 
active site of isomaltase. The ligand was stabilized in the active site of an enzyme by 
surrounding key amino acid residues including Glu277, Asp252, Leu313, and Ser240. The 
docked momordicoside F1 was buried entirely in the α-glucosidase binding pocket with 
part of the molecule reaching the catalytic center comprised of Glu277, Arg442, and 
Asp352, which adequately explains the competitive nature of momordicoside F1; the 
remaining portion of the momordicoside F1 extended towards the protein 
surface. Momordicoside F1 showed a potential inhibition activity of amylase (68.98%), 
and its docking score on this enzyme is the first among the other six scores (-12.08 
kcal/mol). The 3D docking mode (Figure 12D) and 2D schematic (Figure A36D) of 
momordicoside F2 and isomaltase clearly showed that the momordicoside F2 (4) inserted 
into the cavity of isomaltase by surrounding Asp352, Glu277, Pro312, Lys156, Phe314, 
Arg315, Tyr158, and Phe303. These interactions overtly strengthened the interactions 
between momordicoside F2 and isomaltase, resulted in the binding energy of (-11.43 
kcal/mol). Momordicoside G bound to the active site of isomaltase with binding energy -
9.9 kcal/mol. As shown in Figure 12E and Figure A36E, momordicoside G (5) interacted 
with crucial amino acid residues including Ser157 and Ala281, Asn312, Asn415 in the 






Figure 12 The 3D ligand-protein interactions for (A). momordicoside I, (B). momordicoside F1, (C). momordicoside K (D). momordicoside F2, (E). 
momordicoside G, (F). karaviloside XI, and (G). 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid in the binding pocket of -glucosidase respectively. 






However, the attachment of allose sugar moiety at C-3 and attachment of OMe 
group at C-25 in momordicoside G resulted in an altered docking pose compared to other 
compounds. Also, Karaviloside XI (6) with the binding energy of -9.45 kcal/mol occupied 
the active region of isomaltase by interacting with amino acids including Asp 215, Glu277, 
Asp352, and Leu313. Besides, karaviloside XI was utterly inserted in the binding pocket 
of the enzyme by making additional hydrophobic interactions with amino acids residues 
including Phe159, Tyr158, Phe303, Arg315, and His280. All these interactions affected 
the enzyme inhibitory activity significantly and resulted in the binding energy of -12.19 
kcal/mol. 
The refined docking of 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) with 
isomaltase generated the best pose with a minimum binding energy of -7.97 kcal/mol. The 
3D interactions in Figure 12G and 2D schematic Figure A36G shows that compound 7 
established seven hydrogen bonds within the isomaltase enzymatic pocket. The C-1 
(carboxylic acid) formed two hydrogen bonds with Lys156 and Ser240 respectively. 
Similarly, hydroxyl groups at C-3' and C-4' of pentose sugar formed conventional 
hydrogen bonds with Ser241 and Asp242 (two hydrogen bonds) respectively. Also, 2-
hydroxy-5-O-β-D-xylopyranosyl benzoic acid (7) showed the highest % inhibition of α-








4.4.4 In vitro anti-inflammatory activity  
 
Purified compounds (1-7) were tested for anti-inflammatory activity in RAW 
264.7 macrophages, using the bacteria toxin LPS to induce acute inflammation. As 
expected, LPS significantly increased expression of pro-inflammatory genes IL-1β, Cox-
2, IL-6, iNOS, TNF-α, and NF-κB, compared to control (Figure 13). All of the compounds 
tested differentially affected the expression of IL-1β, Cox-2, IL-6, iNOS, TNF-α, and NF-
κB. Also, compounds (1-7) significantly decreased expression of IL-1β when compared to 
the LPS group (p<0.001). It is worth noting that momordicoside G (5), at the concentration 
of 25 µM, was most potent at decreasing the expression of IL-1β. Similarly, in case of 
Cox-2, compounds 1, 2, 3, 6, and 7 significantly suppressed LPS stimulated Cox-2 
expression at 25 µM (p<0.001). Among them, we observed compounds 1, 6 and 7 to be 
potent suppressing agents for the expression of Cox-2. Pre-treatment with compounds 1-
7 significantly suppressed the LPS-stimulated expression of iNOS and NF-κB mRNA 
compared to the LPS treatment group (p<0.001). Momordicoside F1(2) was most potent 
at suppressing the expression of iNOS (p< 0.001), compared to the LPS group. As seen in 
Figure 13, compounds 1, 6 and 7 significantly down-regulated the expression of IL-6, 
compared to the LPS-treated group at 25 µM concentration. Conversely, compound 3 did 
not reduce the expression of IL-6 at 25 µM concentration significantly. Compounds (2), 
(5) significantly suppressed the expression of TNF-α at 25 µM concentration (p< 0.001), 




To date, many natural products have been identified as potential anti-inflammatory 
agents. These natural products, such as triterpenes, could strongly inhibit/attenuate 
inflammatory mediators. Triterpenoids, major bioactive constituents in M. charantia, are 
widely distributed in plants and maybe responsible for bitter melons’ anti-inflammatory 
effects. 153 However, studies relating specific natural compounds of bitter melon to the 
bioactivities of the plant and exploring the underlying mechanisms are limited. In earlier 
studies, compound 5β, 19-epoxy-25-methoxycucurbita-6, 23-diene-3β, 19-diol (16, 
EMCD) isolated from M. charantia was evaluated for anti-inflammatory activities against 
TNF-α induced inflammation via AMPK in FL83B cells. EMCD inhibits TNF-α induced 
expression of iNOS, NF-κB, protein-tyrosine phosphatase-1B, TNF-α, and IL-1β. 154  In 
another study, the active constituents of M. charantia,  1-α-linolenoyl-
lysophosphatidylcholine (LPC) and 1-linoleoyl-LPC suppressed the LPS-induced TNF-α 
production in RAW 264.7 cells at a concentration of 10 µg/mL 107. In the present study, 
momordicoside I (1), momordicoside K (3), karaviloside XI (6) and 2-hydroxy-5-O-β-D-
xylopyranosyl benzoic acid (7) were determined as the most potent anti-inflammatory 
compounds by demonstrating their effects on the levels of the pro-inflammatory markers, 
including IL-1β, Cox-2, IL-6, iNOS and NF-κB in LPS-stimulated RAW 264.7 cells.  
NF-kB is a key transcriptional regulator of the inflammatory response and plays a 
vital role in the development of the inflammatory process and cellular injuries. It is 
activated in response to different extracellular stimuli, including oxidative stress, LPS, and 
cytokines. 155  NF-kB enters the nucleus and activates the transcription of pro-




COX-2, resulting in inflammation. In the present study, LPS could induce the 
translocation of NF-κB and promotes expression of pro-inflammatory factors, whereas all 
tested compounds significantly reduced the expression of NF-κB compared to LPS 
treatment group, subsequently attenuating expression of pro-inflammatory genes. To the 
best of our knowledge, this is the first-time anti-inflammatory activity by cucurbitane-type 








Figure 13 Effect of purified compounds (1-7) at on mRNA expression of IL-1β, IL-6, TNF-α, INOS, NF-
κB and Cox-2 on LPS induced murine macrophage RAW 264.7 cells. The cells were pretreated with 25 
µM compounds 1. momordicoside I, 2. momordicoside F1, 3. momordicoside K, 4. momordicoside F2, and 
5. momordicoside G, 6. karaviloside XI and 7. 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid then LPS 
(1μg/ml) was added and incubated for 18 h. Data are expressed as mean ± SD (n=9), and analyzed by one-
way ANOVA. Different letters within the same panel indicate there were significant differences at 
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In this study, ten compounds were isolated from the fruit of M. charantia. 
Compounds 1-7 showed variable α-amylase and α-glucosidase inhibitory activities, 
ranging from 35–75%. Molecular docking studies showed that compounds 1-7 had a high 
affinity close to the active site of both enzymes by interacting with key amino acid 
residues. Also, the anti-inflammatory activities of compounds (1-7) demonstrated that 
momordicoside I (1), momordicoside K (3), karaviloside XI (6) and 2-hydroxy-5-O-β-D-
xylopyranosyl benzoic acid (7) are the most effective anti-inflammatory agents, 
suppressing the expression of pro-inflammatory markers IL-1β, Cox-2, IL-6, iNOS, TNF-
α and NF-κB in LPS-stimulated RAW 264.7 cells. Overall, the results presented here 
indicated that compounds isolated from bitter melon are worthy of further investigation in 




  CHAPTER 5  
SUMMARY AND CONCLUSIONS 
 
Existing literature suggests that M. charantia consists of an array of natural 
compounds, which makes it functional food, especially in the reducing risk from diabetes. 
However, the exact role of each of these compounds in the overall observed antidiabetic 
and anti-inflammatory potential of M. charantia is still obscure. In the present study, 14 
bioactive compounds were isolated from the medium polar and polar extracts of M. 
charantia. The structures of the isolated compounds were characterized by 1D and 2D 
NMR and high-resolution mass spectroscopic data. Charantoside XI and 2-hydroxy-5-O-
β-D-xylopyranosyl benzoic acid were the two purified novel compounds from M. 
charantia. Charantoside XI is the first example of cucurbitane triterpene containing 
carboxylic group at position 3. Also, TCD and charantal were purified first time from the 
edible part of M. charantia. 
Similarly, momordicoside I, F1, K, F2, and G were previously isolated from the 
fruit of M. charantia. However, there is no precise, complete NMR data available for these 
compounds. Hence, this study presented complete NMR data for these compounds. In case 
of bioactivity, IDG was the most potent compound and exhibited higher inhibition of 
carbolytic enzymes compared to the other compounds and comparable activity to that of 
acarbose. Similarly, triterpene glycosides momordicoside G and K showed potent α-
amylase inhibitory activity. Novel compound, 2-hydroxy-5-O-β-D-xylopyranosyl benzoic 




inhibition of these enzymes in the pancreas and brush border membrane of small intestine 
regulates the digestion of complex carbohydrates, which in turn controls the blood 
glucose. Also, The inhibitory mechanism of these compounds significantly varied due to 
conformational changes derived from the presence of a sugar moiety in some of the 
compounds.  
Similarly, in the present study, polar compounds karaviloside XI has a sugar 
moiety and having multiple hydroxyl groups showed strong α-glucosidase inhibitory 
activity compared to other cucurbitane mono glycosides. Interestingly we also observed 
in α-glucosidase inhibitory activity compounds bearing a β-D-allopyranosyl group at C-3 
exhibited higher inhibitory activity than compounds bearing a β-D-glucopyranosyl group 
at C-3.  
Antidiabetic activity was further confirmed by SAR through the help of molecular 
docking studies. The elven compounds from M. chrantia all showed competitive 
inhibition against porcine pancreatic α-amylase and isomaltase. They demonstrated 
different inhibition activities, among which IDG had the highest one. The molecular 
docking study showed that all the eleven purified compounds occupied the active site of 
porcine pancreatic α-amylase and isomaltase forming hydrogen, pi-alkyl bonds. In the 
case of α-amylase GLU233, ASP300 and ASP197 were found to be the common key 
residues for imparting the inhibition activity of all the eleven compounds. In the case of 
isomaltase molecular docking studies, compounds were able to form hydrogen bonds key 
amino acid residues on isomaltase including ARG442 and GLU277. Overall, results 




compounds from bitter melon to better design novel functional foods with slow-releasing 
sugars, thereby lowering the risk of postprandial hyperglycemia which is characterized as 
early Type II diabetes. 
Meanwhile, TCD (1) and charantoside XI, momordicoside I, momordicoside K, 
karaviloside XI, and 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid were determined as 
the most potent anti-inflammatory compounds by demonstrating their effects on the levels 
of the pro-inflammatory markers, including IL-1β, Cox-2, IL-6, iNOS and NF-κB in LPS-
stimulated RAW 264.7 cells. Our findings suggest that these compounds purified from 
bitter melon have potential anti-inflammatory activities and therefore hold promise for 
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Position Compound 3 MeOH-d4 
 δ H (ppm) δ C (ppm) 
1 1.65; 1.70 m 22.7 
2 1.87; 2.00 m 27.0 
3 4.82 m 81.1 
4 - 41.2 
5 - 146.5 
6 5.93 dd, 1H (J= 5.6; 1.6 Hz) 124.2 
7 4.03 d, 1H ( J= 5.4 Hz) 66.9 
8 1.94 br s, 1 H  51.3 
9 - 51.2 
10 2.65 dd, 1H (J = 13.2, 4.3 Hz) 37.3 
11 1.48; 2.39 m 23.3 
12 1.42; 1.98 m 28.7 
13 - 46.8 
14 - 48.8 
15 1.40; 1.40 m 35.7 
16 1.68; 1.68 m 30.2 
17 1.56 m 51.4 
18 0.92 s, 3H 15.5 
19 9.84 s, 1H 209.4 
20 1.55 m 37.7 
21 0.92 d, 3H 19.3 
22 1.78; 2.16 m 40.4 
23 5.58 m, 2H 125.9 
24 5.58 m, 2H 141.0 
25 - 71.3 
26 1.25 s, 6H 30.3 
27 1.25 s, 6H 30.2 
28 1.17 s, 3H 27.5 
29 1.21 s, 3H 25.6 
30 0.82 s, 3H 18.8 





Figure A1 High-resolution mass spectra by electrospray chemical ionization of purified compounds (1, 2 















































































Figure A2 Complete assignments of 1HNMR spectrum of compound 1 (CDCl3), recorded on a JEOL ECS NMR spectrometer at 400 MHz, solvent 



















Figure A4 Complete assignments of 1HNMR spectrum of compound 2 (CDCl3), recorded on a JEOL ECS NMR spectrometer at 400 MHz, solvent 

















Figure A6 Complete assignments of 1HNMR spectrum of compound 4 (C5D5N), recorded on a JEOL ECS NMR spectrometer at 400 MHz, solvent 




































Figure A8 Identification of compound 3 by UV spectra and mass spectral analysis.  (A). HPLC 
chromatogram of compound 3, (B). UV spectra, high resolution mass spectra obtained from (C). 
Electrospray ionization by positive mode and (D). Atmospheric pressure chemical ionization. Both the 





Figure A9 Complete assignment of HMQC spectra of compound (3) (charantoside XI). Spectrum was recorded in CD3OD. 1H-NMR spectrum on X-





Figure A10 Complete assignments of 1HNMR spectrum of compound 3 (CD3OD), recorded on a JEOL ECS NMR spectrometer at 400 MHz, solvent 























Figure A14 The 2D ligand-protein interactions of purified compounds (A). 3β,7β,25-trihydroxycucurbita-
5,23(E)-dien-19-al, (B). charantal, (C), charantoside XI and (D).  25ξ-isopropenylchole-5, 6-ene-3-O-D-
glucopyranoside with α-amylase enzyme. Legends below the figure shows the different types of bonding 



















Figure A15 2D ligand-protein interactions of purified compounds (A). 3β,7β,25-trihydroxycucurbita-
5,23(E)-dien-19-al, (B). charantal, (C), charantoside XI and (D).  25ξ-isopropenylchole-5, 6-ene-3-O-D-
glucopyranoside with α-glucosidase enzyme. Legends below the figure shows the different types of 
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Figure A17 Complete assignments of 1H-NMR spectra of compound 1 in MeOD, recorded at 400 MHz. using standard JEOL pulse programs. The 







Figure A18 Complete assignments of 13CNMR spectra of compound 1 in MeOD, recorded at 100 MHz using standard JEOL pulse programs. The 
































































Figure A29 High-resolution mass spectra of purified compounds (1-7) from the acetone and methanol 














































































































































































































































Figure A30 (A) HPLC Chromatogram of compound 7and (B). UV spectrum of compound 














Figure A31 Complete assignments of 1HNMR spectra of compound 7 in MeOH, recorded at 400 MHz using standard JEOL pulse programs. The 


























Figure A35 The 2D ligand-protein interactions for (A). momordicoside I, (B). momordicoside F1, (C). momordicoside K, (D). momordicoside F2, (E). 
momordicoside G, (F). karaviloside XI and (G). 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid in the binding pocket of -amylase. Legends below 
each figure are showing types of bonding between a compound and the enzymatic pocket of α-amyalse. 
 
 










Figure A36 The 2D ligand-protein interactions for (A). momordicoside I, (B). momordicoside F1, (C). momordicoside K, (D). momordicoside F2, (E). 
momordicoside G, (F). karaviloside XI and (G). 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid in the binding pocket of -amylase. Legends below 
each figure are showing types of bonding between a compound and the enzymatic pocket of isomaltase. 
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